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Abstract 
 
Urothelial cell carcinoma (UCC) of the bladder is a common malignancy worldwide, causing 
considerable morbidity and mortality.  It is unique among epithelial carcinomas in respect of 
the fact that it has divergent pathways of tumourigenesis.  Low-grade papillary tumours which 
frequently recur, but seldom convert to muscle invasive tumours harbour mutations that 
activate the MAPK pathways, as a consequence of oncogenic mutations in FGFR3 or HRAS. 
However, in contrast, the high-grade muscle invasive tumours that readily metastasise have 
been shown to have defects in the p53 and retinoblastoma (RB) protein pathways  
Transgenic mice have allowed us to analyse the molecular basis of initiation, invasion and 
progression of many human cancers.  These mouse models increase our understanding of the 
disease process as well as providing targets for developing novel therapeutic approaches.  In 
UCC there has been a paucity of models that readily mimic the human disease.   
Although deregulation of the Wnt signalling pathway has been implicated in urothelial cell 
carcinoma (UCC), the functional significance is unknown. Recent studies have demonstrated 
the importance of this pathway in UCC progression, thus I endeavoured to test its importance 
both as a “driver” mutation, as well as a “progressor” mutation in more established UCC 
mutations. Thus I targeted expression of an activated form of β-catenin to the urothelium of 
transgenic mice using Cre-Lox technology.  Expression of this activated form of β-catenin led 
to the formation of localised hyperproliferative lesions by 3 months, which did not progress to 
malignancy. Furthermore expression in UroIICRE+ β-cateninexon3/+ mice showed marked 
upregulation of the PTEN tumour suppressor protein that appears to be a direct consequence 
of activating Wnt signalling in the bladder.  I therefore combined PTEN deficiency with β-
catenin activation, which resulted in rapid formation of papillary UCC by 6 months. These 
tumours had increased pAKT signalling and were dependent on mTOR. Importantly in human 
16 
 
UCC, there was a significant correlation between high levels of β-catenin and pAKT (and low 
levels of PTEN) (p<0.01, n=80).  Taken together, these data suggest that deregulated Wnt 
signalling plays a role in driving UCC, and human UCC that have high levels of Wnt and PI3 
kinase signalling may be responsive to mTOR inhibition. 
I next expressed oncogenic K-Ras or H-Ras in the urothelium alone, and in urothelial cells 
expressing an activated β-catenin. Although Ras activation was not sufficient to drive 
tumourigenesis, Ras activation combined with β-catenin activation in UroIICRE+ β-
cateninexon3/exon3 K-RasG12D/+ and UroIICRE+ β-cateninexon3/exon3 H-RasQ61L mice rapidly 
developed UCC. These tumours had upregulation of pERK1/2 with minimal levels of pAKT. 
Importantly in human UCC, there was a significant correlation between high levels of β-
catenin and pERK1/2 (p<0.01, n=80).  This data further supports the role of deregulated Wnt 
signalling and its co-operation with Ras in bladder carcinogenesis. 
I observed upregulated p21 expression in our UroIICRE+ β-cateninexon3/+urothelial lesions 
and thus postulated that p21 may be acting as a block to tumourigenesis in the lesion. It was 
highly relevant to observe tumour formation in the double mutant UroIICRE+ β-
cateninexon3/exon3 p21-/- mice. 
FGFR3 gene is frequently mutated in superficial urothelial cell carcinoma (UCC).  To test the 
functional significance of FGFR3 mutations as a “driver” of UCC, expression of mutated 
Fgfr3 was targeted to the murine urothelium using UroIICRE+ promoter. These FGFR3 
mutations (K644E and K644M) had no effect on bladder homeostasis or tumourigenesis up to 
18 months of ages. Even when these mutations were combined with β-Catenin or Ras 
activating mutations, no urothelial dysplasia/hyperplasia or UCC was observed. This suggests 
that other alterations are required that can cooperate with FGFR3 activation to cause UCC. 
Interestingly, however, due to sporadic ectopic Cre recombinase expression in the lung and 
17 
 
skin of these mice, FGFR3 mutation caused skin papilloma and promoted lung 
tumourigenesis in cooperation with K-Ras and β-Catenin activation, respectively. This 
confirmed that the mutant Fgfr3 was functional and that FGFR3 cooperates with other genetic 
events involving Ras and Wnt pathways to promote tumourigenesis in a context dependent 
manner and support the hypothesis that activation of FGFR signaling contributes to human 
cancer. 
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1. Introduction to Urothelial Cell Carcinoma 
1.1. Urothelial Cell Carcinoma Epidemiology 
 
Urothelial cell carcinoma (UCC) is a significant health problem worldwide, with its 
prevalence continuing to rise.  In the U.K. it is the 4th most common cancer in males, with 
7306 new cases in 2006. In comparison, there were only 2957 female cases, making it the 11th 
most common female cancer. Worldwide there is an estimated 356600 new cases diagnosed 
yearly, and in terms of overall cancer frequency, it is ranked 9th. (Cancer Research UK - 
http://info.cancerresearchuk.org/cancerstats/types/bladder/incidence/index.htm ). 
It is a relatively rare disease in under 50s, but the rates rise and peak in the oldest age group, 
where the male to female ratio becomes 3:1 (Figure 1.1). 
The highest incidence rates are found in industrially developed countries, particularly in the 
West, and in areas associated with endemic schistosomiasis such as Africa and the Middle 
East.  
Marked racial differences have been reported for bladder cancer incidence with higher rates in 
Caucasian populations (e.g. US rates in caucasians are double those for black men) (National 
Cancer Institute - http://seer.cancer.gov/csr/1975_2003/ ). 
Looking at the bladder cancer incidence rates over time, it is difficult to interpret because of 
changes in the classification of muscle invasive disease of the bladder. In spite of this 
difficulty Cancer Research UK have demonstrated that the age-standardised incidence rates 
per 100,000 population rose throughout the 1970s and 1980s to reach a peak of 32 in men and 
9 in women in the early 1990s and since then have fallen by around a third (Figure 1.2). This 
fall could be attributed to tighter regulation of occupational factors.  This trend will most 
probably continue since the passing of legislation banning cigarette smoking in public place, 
reducing active and passive smoking rates. 
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Figure 1.1: Numbers of new cases and age-specific incidence rates, by sex, bladder 
cancer, UK 2006 
 (Source Cancer Research UK 
http://info.cancerresearchuk.org/cancerstats/types/bladder/incidence/index.htm)  
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Figure 1.2: Age standardised incidence rates, bladder cancer, by sex, UK, 1975-2006 
(Source Cancer Research UK 
http://info.cancerresearchuk.org/cancerstats/types/bladder/incidence/index.htm)  
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1.2 Pathophysiology of the Urothelium 
 
Urothelium, from which all UCC arise, is histologically a stratified and polarised epithelium 
(Khandelwal et al., 2009). It is composed of a single cell type, with differences in layers 
attributed to degrees of cellular differentiation.  It acts as a physiological and mechanical 
barrier between urine and blood. It acts to protect the underlying tissues from toxic urinary 
substances, as well as adjusting its surface area during bladder filling (Negrete et al., 1996). 
The urothelium is extremely stable, with cells turning over very slowly (turnover rate 
approximately every 200 days with a tritium-thymidine labelling index of less than 0.01%) 
(Hicks, 1975, Walker, 1960). 
Cells in the basal layer are the smallest in size and least differentiated. This is where the 
majority of proliferation occurs and where the stem cell niche may reside (Kurzrock et al., 
2008).  This layer is the only urothelial layer to express appreciable levels of epidermal 
growth factor (EGF) receptor, but this is protected from the high concentration of EGF in the 
urine due to the barrier afforded by the superficial urothelial layer (Messing, 1990, Messing, 
1992). Similarly, the basal (and presumed stem cells) are well protected from carcinogens, by 
a differentiated layer of intermediate cells (3-4 layers in humans, single in murine) (Wu et al., 
2009). 
The superficial urothelial cells facing the bladder lumen, also called umbrella cells, are 
distinctive large, terminally differentiated, polyhedral and bi-nucleated cells and are thought 
to be derived from intermediate cells through cell fusion (Koss, 1969). The umbrella cells 
contribute to form an asymmetrical membrane that lines over 95% of the luminal surface of 
the urothelium. Within this layer, the four major uroplakins (Ia, Ib, II and IIIa), luminal 
protein complexes restricted to the urothelium, are expressed (Wu et al., 2009).  
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1.3. Classification of Urothelial Cell Carcinoma 
 
Clinical and pathological studies have found that development of UCC in humans arise from 
at least 2 separate mechanisms (Wu, 2005, Koss, 1992). The vast majority of these are 
transitional cell carcinomas (TCC). About 70% of the incidence is due to papillary, non-
invasive tumours (TaT1) (Table 1.1) that despite local excision tend to recur in over 30% of 
patients but progress to invasive disease in 10-20% of these cases (Knowles, 2001). In 2004, 
the revised classification of non-invasive urothelial tumours was proposed by the World 
Health Organization (WHO) and the International Society of Urological Pathology (ISUP) 
(1998 WHO/ISUP classification) (Eble JN, 2004) (Table 1.1).  
Carcinoma in situ (CIS) is recognisable as flat, anaplastic epithelium. The urothelium lacks 
the normal cellular polarity, and cells contain large, irregular hyperchromatic nuclei with 
prominent nucleoli. CIS may occur either close to or remote from an exophytic lesion or, 
rarely, it may occur as focal or diffuse lesions in a patient without macroscopic tumours. It 
has a variable natural history, but many cases progress to invasive disease. In addition, 
exophytic lesions occurring with CIS are more likely to recur and invade than those without 
CIS.  The frequency of tumour invasion, recurrence, and progression is strongly correlated 
with tumour grade (Eble JN, 2004). 
 
 
 
 
 
 
24 
 
 
 
 
 
 
 
Table 1.1: WHO grading in 1973 and in 2004 
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The majority of mortality is associated with patients with non-papillary, muscle invasive TCC 
(20-30% of all cases). These invasive tumours can penetrate deeply through the muscle wall 
of the bladder and 50% will relapse with metastases to distant sites despite radical therapy 
(Williams and Stein, 2004). Treatment fails in 95% of patients with advanced disease, and the 
5-year survival rate for metastatic bladder cancer is only 6% (Table 1.2 and Figure 1.3). 
 
 
Table 1.2: 2002 Tumour, Nodes, Metastases Classification (2002) 
The 2002 TNM classification has been approved by the Union Contre le Cancer (UICC) 
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Figure 1.3: T Staging of bladder cancer 
(Source Cancer Research UK 
http://info.cancerresearchuk.org/cancerstats/types/bladder/survival/index.htm )  
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1.4. Divergent Molecular Pathways of Urothelial Cell Carcinoma 
 
Both clinical and experimental evidence indicate that UCCs arise and progress along two 
distinctive pathways (Figure 1.4). The low-grade, superficial/papillary UCCs harbour frequent 
mutations in the HRAS gene (30–40%) and fibroblast growth factor receptor 3 (FGFR3) gene 
(~70%), indicating that RTK (Receptor Tyrosine Kinase)–Ras activation has an early and 
crucial role in this tumourigenesis pathway (Jebar et al., 2005). Deletions in the short arms of 
chromosomes 8 and 11 (8p– and 11p–) and long arms of chromosomes 13 and 14 (13q– and 
14q–) are often associated with the rare cases of progression to the muscle invasive stages of 
UCC (Wu, 2005).  
The high-grade muscle-invasive tumours can either originate from carcinoma in situ (CIS) or 
arise de novo. Over 50% of these tumours contain mutations in the tumour suppressors p53 
and/or the retinoblastoma protein (RB). Invasion and metastases are promoted by several 
factors that alter the tumour microenvironment, including the upregulation of N- cadherin (N-
Cad) and downregulation of E-cadherin (E-cad), matrix metalloproteinases (MMPs), 
angiogenic factors (e.g. vascular endothelial growth factor (VEGF)), and antiangiogenic 
factors (e.g. thrombospondin 1 (TSP1)) and cyclooxygenase 2 (COX2) (Garcia del Muro et 
al., 2000, Shariat et al., 2001, Popov et al., 2000, Ribeiro-Filho et al., 2002, Zhang et al., 
2003, Rieger-Christ et al., 2004, Vihinen and Kahari, 2002, Kanayama, 2001, Izawa et al., 
2001, Slaton et al., 2001, Campbell et al., 1998, Grossfeld et al., 1997, Komhoff et al., 2000). 
Deletion of both arms of chromosome 9 (9p–/9q–) occurs early during urothelial 
tumourigenesis in both tumour pathways (Chow et al., 2000, Obermann et al., 2003). Further 
elucidation of the genetic and epigenetic causes of the two distinctive pathways of UCC will 
have a great impact on the management of this disease condition. 
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Figure 1.4: Important genetic and epigenetic defects that characterise the divergent 
pathways of UCC.   
Little work has been done on the PTEN and Wnt pathways in bladder cancer, thus their 
exclusion from this diagram.  
(Adapted from Wu, 2005) 
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Recent sequencing of human UCC by the Sanger institute in Cambridge has confirmed a 
number of these mutations are indeed present in human UCC 
(http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=byhist&ss=bladder&sn=urinary_t
ract&s=3) (Figure 1.5). 
  
 
 
 
Gene Name Sample Number Positive Samples Percent Mutated 
FGFR3 3554 1668 47% 
CDKN2A 1241 189 15% 
HRAS 1166 135 12% 
PIK3CA 361 83 23% 
KRAS 470 19 4% 
Figure 1.5: Mutation profile of human UCC 
Unfortunately these sequenced tumours are a mixture of non-invasive and invasive UCC 
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1.5. Risk Factors for Urothelial Cell Carcinoma  
1.5.1. Tobacco Smoking 
 
Tobacco smoking is the most well established risk factor for bladder cancer, causing about a 
half of male cases and a third of female cases (Brennan et al., 2000). The carcinogenic 
contents of tobacco smoke include arylamines (particularly 4-aminobiphenyl), polycyclic 
aromatic hydrocarbons (PAHs), N-nitroso compounds, heterocyclic amines and a variety of 
epoxides. The incidence of bladder cancer is related directly to the duration of smoking and 
number of cigarettes smoked per day (Brennan et al., 2000). There is also a higher risk of 
bladder cancer in those who start smoking at a young age and those exposed to passive 
smoking during childhood (Bjerregaard et al., 2006). An immediate decrease in the risk of 
bladder cancer has been observed in those who quit smoking. This reduction was about 40% 
within 1-4 years of quitting smoking and reached 60% after 25 years of cessation (Brennan et 
al., 2000).  
 
1.5.2. Occupational Exposure to Chemicals 
 
Occupational exposure to chemicals is the second most important risk factor for bladder 
cancer. Work-related cases account for a quarter of all bladder cancer cases in several case 
series (Pashos et al., 2002, Kogevinas et al., 2003). The substances implicated include 
benzene derivatives and arylamines (2-naphthylamine, 4-ABP, 4, 4’-methylenedianiline and 
o-toluidine). At risk professions include those that use dyes, rubbers, textiles, paints, leathers 
and chemicals (Pashos et al., 2002). However due to the introduction of strict regulations in 
the West, these chemicals have had minimal contribution to the current incidence of bladder 
cancer. In fact, there has been a decrease in bladder cancer due to occupational exposure as 
reported in a pooled analysis of 11 European case control studies on bladder cancer conducted 
between 1976 and 1996 (Kogevinas et al., 2003). Another source of occupational exposure 
31 
 
are the aromatic amines. A metabolic acetylation pathway can inactivate them and it had been 
hypothesised that patients with slow acetylation capability were more susceptible to bladder 
cancer than rapid acetylators.  N-acetyltransferase genes 1 and 2 (NAT1 and NAT2) are 
mapped to the short arm of human chromosome 8, are involved in amine inactivation. The 
presence of an NAT2 slow acetylation genotype has been related to a higher risk of bladder 
cancer (Garcia-Closas et al., 2005). Other risk factors include analgesic phenacetin. Some 
studies have suggested that the risk of bladder cancer due to phenacetin is dose-dependent; 
however, the data is controversial concerning its metabolite paracetamol (acetaminophen) 
(Castelao et al., 2000). 
 
1.5.3. External beam radiation therapy 
 
Increased rates of “secondary” bladder carcinomas have been reported in the literature after 
external beam radiation therapy (EBRT) for gynaecological malignancies (Chrouser et al., 
2008, Chrouser et al., 2005). Similarly, in patients treated for prostate cancer by EBRT the 
rates of bladder malignancy were higher than those subjected to surgery alone (Boorjian et al., 
2007). 
 
1.5.4. Dietary factors 
 
To date, there is limited evidence of a causal relationship between bladder cancer and dietary 
factors. A meta-analysis of 38 articles reporting data on diet and bladder cancer supported the 
hypothesis that high intake of vegetable and fruit is associated with reduced the risk of 
bladder cancer (Steinmaus et al., 2000). 
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1.5.5. Chronic urinary tract infection 
 
Muscle-invasive squamous cell carcinoma (SCC) is directly related to the presence of chronic 
urinary tract infection. Similarly bladder schistosomiasis has been considered a definitive 
cause of urinary bladder cancer with an associated five-fold risk. Schistosomiasis is the 
second most common parasitic infection after malaria, with about 600 million people exposed 
to the infection in Africa, Asia, South America and the Caribbean (Johansson and Cohen, 
1997).  
Cyclophosphamide, an alkylating agent, has been correlated with development of posterior 
muscle-invasive bladder cancer with a latency period of 6 to 13 years. Acrolein is a 
metabolite of cyclophosphamide and is responsible for an increase in the incidence of bladder 
cancer and is independent of the occurrence of haemorrhagic cystitis related to the same 
treatment (Kaldor et al., 1995, Travis et al., 1995). 
 
1.5.6. Gender 
 
Differences in the gender prevalence for bladder cancer may be related to differences in 
oestrogen and androgen levels between men and women (McGrath et al., 2006). 
Interestingly in radical cystectomy patients, it has been demonstrated that women are more 
likely to be diagnosed with primary muscle-invasive disease than men (85% vs. 51%) (Vaidya 
et al., 2001). It may be that women are likely to be older than men when diagnosed with a 
direct effect on their survival. This is however in direct contrast to Cancer Research UK 
figures (Section 1.1) where UCC is more prevalent in males. 
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1.6. Murine Models of Urothelial Cell Carcinoma 
 
Until very recently the murine models of UCC have been very limited.  One aim of this thesis 
is to create a better model of UCC.  Attempting to elucidate the molecular mechanisms behind 
UCC in cell lines/tissue culture is hampered by its artificial nature as well as the lack of 
stroma/microenvironment. Murine models are required to satisfy our desire for increased 
understanding of the molecular basis of UCC and to explore treatment regimes aimed to 
improve patient outcome. 
Although mice do not spontaneously develop bladder cancer, the murine models of human 
cancer have provided new tools for the investigation of bladder carcinogenesis.  In many other 
diseases murine models have provided invaluable information regarding pathogenesis and 
novel disease approaches e.g. cystic fibrosis (Guilbault et al., 2007).  In this disease the 
variety of models reflect that different aspects of the heterogenicity of phenotypes observed in 
humans; intestinal, pancreatic, hepatobilary and lung disease as well as ones reflecting the 
increased susceptibility to respiratory infections. 
In the past murine bladder cancer models included the orthotopic approach using primary or 
genetically altered cell lines derived from localised and metastatic disease and chemical 
carcinogen techniques.  
 
1.6.1. Chemically induced carcinogenesis 
 
Spontaneous bladder cancers in mice (and rats) are very rare, thus intravesical installation of 
carcinogens is frequently used. The most commonly used carcinogens are N-butyl-N-(4-
hydroxybutyl) nitrosamine (BBN), N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) 
and N-Methyl-N-nitosurea (MNU). They are used particularly for chemoprevention studies, 
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although novel treatments can be tested and molecular mechanisms elucidated (Black and 
Dinney, 2007).   
BBN is the most widely studied of these agents, since the lesions closely resemble those 
found in human UCC. Recent work has attempted to profile the gene expression in these 
murine and rodent tumours and correlate them with human UCC (Williams et al., 2008).  
They found that many human genes homologous to those differentially expressed in the 
rodent tumours were also differentially expressed in the human disease and were 
preferentially associated with progression from non-invasive to muscle invasive disease. They 
were predominantly cell cycle genes, as well as RAC GTPase-activating protein (RACGAP1) 
and N-myc downstream-regulated gene 2 (NDRG2).  Also interestingly they found that the 
overall gene expression profiles of rodent tumours corresponded more closely with those of 
muscle invasive tumours than the non-invasive ones. 
Advantages of chemically induced carcinogenesis include that these agents are specific to the 
urothelium, with 100% of mice developing carcinoma of the bladder. However the process of 
tumour induction takes 8-14 months and there are safety issues surrounding the exposure of 
lab/animal unit staff to carcinogens. 
 
1.6.2. Orthotopic Models 
 
There are two forms of orthotopic murine UCC (bladder) models utilised: 
1. Orthotopic xenograft models (i.e. implantation of human bladder cancer cells into a 
nude mouse) 
2. Orthotopic syngeneic models (i.e. implantation of murine bladder cancer cells in 
immunocompetent mice) 
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1.6.1.1. Orthotopic xenograft models 
 
In these models human TCC cells are implanted into the immunodeficient host mouse. 
Several TCC cell lines have been used in this fashion including KU7, KU-19, T24 and UM-
UC3 cell lines. A major disadvantage of this technique is that the immune response, which is 
known to be essential to allow treatment with intravesical agents (that is agents instilled 
directly into the bladder) such as Bacillus Calmette-Guerine (BCG) and mitomycin C cannot 
be assessed in these immuno-compromised mice. 
Dinney and colleagues in 1995 established the first reliable orthotopic model of bladder 
cancer by direct intravesical implantation of the human 253J TCC cells into the bladder of 
nude mice (Dinney et al., 1995). However many researchers continue to experiment with 
subcutaneous xenograft models, but as was demonstrated by Perrotte and colleagues results 
with ectopic tumour inoculation may not reflect what is found with orthotopic models. They 
used 253J-B-V cells and after 28 days of tumour growth found although tumour size was 
similar in the ectopic and orthotopic models, however only the orthotopic models developed 
metastasis to lymph nodes and lung. When these orthotopic models were analysed they found 
an increase in microvessel density and a corresponding increase in vascular endothelial 
growth factor (VEGF) and fibroblast growth factor (FGF) expression and MMP-9 activity, 
demonstrating the importance of microenvironment on tumour cells and their ability to 
metastasise. Again, however this is limited since the normal microenvironment of the murine 
bladder may not represent the normal (or indeed abnormal) microenvironment that is found in 
humans. In these studies single clones of tumours cells are used, when in reality human UCC 
is indeed a heterogenous condition. Multiple clonal subpopulations arise within the tumour, 
all of which have differential abilities to invade and metastasise as well as specific responses 
to treatments. 
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Further refinements to these models have allowed tagging of these cell lines with either GFP 
or luciferase technologies for the assessment of tumour burden and ultimately response 
(Tanaka et al., 2003, Hadaschik et al., 2007). 
 
1.6.1.2. Orthotopic syngeneic models 
 
In these syngenic models, bladder tumours are placed in mice of the same immune status from 
which the tumours cells were originally derived. The MB49 which contains a mutation in 
codon 12 of the K-Ras gene (from 7,12-dimethylenzanthacene-induced bladder tumour in 
C57BL/6 mouse) and MBT-2 which has lost p53 (from FANFT-induced bladder tumour in 
C3H/He mouse) cell lines are the most frequently used (Luo et al., 1999, Soloway, 1977, 
Summerhayes and Franks, 1979, Wada et al., 2001). 
One concern with this model (as in any orthotopic model) is that the ‘take’ rate of tumour 
implantation varies from as low as 30% up to 100% (Chan et al., 2009). Factors influencing 
tumour ‘take’ include tumourigenicity of tumour cells, number of cells implanted, duration 
implanted for and pre-treatment methods (e.g. traumatisation of urothelial mucosa before 
inoculation with cells) (Chan et al., 2009).  Furthermore multiple passages of these cells either 
in vitro or in vivo will result in numerous genetic events occurring in these cell lines. 
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1.7. Transgenic Models 
 
Transgenic murine bladder models have evolved into important tools for research into UCC, 
and have been instrumental in elucidating the two pathways of non-invasive (superficial) 
papillary and muscle invasive bladder cancer (Wu, 2005). The mutations modelled in the 
mouse are those found in the human disease and have allowed researchers to further study the 
underlying molecular mechanisms. Such transgenic models allow researchers to study single 
and/or compound mutational events involving oncogenes and tumour suppressors in an organ 
specific temporal fashion. There are currently two approaches this can be achieved. 
Firstly, the traditional method has been a genome wide knock out of the gene in question 
(Capecchi, 1994).  The major problem is that it does not allow evaluation of the gene function 
if it results in embryonic lethality or premature death.  Also, since the gene is knocked out in 
all cell types, it is difficult to prove that the abnormal phenotype did not arise from a 
developmental defect (Copp, 1995).  Secondly one may use a conditional gene knock out 
technique that aims to overcome many of the above limitations.  The Cre-loxP recombination 
is one of these technologies, which allows one to study conditional cell type and tissue 
specific deletion of genes (Figure 1.5) (Nagy, 2000).  The bacterial Cre- (Cre: Cause 
Recombination) LOXP1 (locus of X-over P1) system has been used in mammalian cells 
(Sauer and Henderson, 1988).  This system relies on a sequence specific DNA cre 
recombinase  which mediates intramolecular recombination and deletion of DNA between 
loxP sequences. LoxP sequences are small sequences of DNA of 34 base pairs.  Using gene 
targeting LoxP flanked alleles have been generated, allowing deletion of genes upon 
expression of cre recombinase.  To permit gene deletion in the tissue of interest, tissue 
specific Cre transgenes have been generated so that currently genes can be deleted in nearly 
every tissue of the mouse, including the bladder urothelium. 
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In addition invasive tumours that develop metastasis provide an excellent platform for 
investigating specific genetic events involved in the metastatic phenotype, including the 
contribution that stromal-epithelial interactions may have. 
Limitations include long latency, incomplete penetrance and often the requirement of an 
artificial promoter (some models use knock-in endogenous alleles which mutate the allele in 
question, whilst others have overexpression of alleles to non-physiological levels).  Tumours 
developed in transgenic models tend to be less heterogeneous than in human bladder tumours, 
which may have an impact on tumour progression and distant spread. Given that no model has 
progressed to bone metastases, some investigators have questioned their relevance to the 
human cancer. 
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Figure 1.6: The Cre-LoxP recombination system in transgenic mice 
The bacterial Cre- (Cre: Cause Recombination) LOXP1 (locus of X-over P1) system relies on 
a sequence specific DNA cre recombinase which mediates intramolecular recombination and 
deletion of DNA between loxP sequences. Using gene targeting LoxP flanked alleles have 
been generated, allowing deletion of genes upon expression of cre recombinase.  To permit 
gene deletion in the urothelium, urolthelial specific Cre transgenes have been generated. 
[Adapted from (Ahmad et al., 2008)] 
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1.7.1. Ras Pathway 
1.7.1.1. HRAS 
 
This was the first human oncogene isolated in human UCC, being mutated most often at 
either codon 12, 13 or 61 (Reddy et al., 1982). Mutation allows it to become constitutively 
active, as well as resulting in overexpression at the protein level (due to alternative splicing of 
the last intron). Despite the controversy regarding the reported mutation frequency rate recent 
studies indicate that HRAS mutation occurs in approximately in 30-40% of UCC (Bentley et 
al., 2009, Czerniak et al., 1992). 
Transgenic models have provided invaluable information regarding the molecular 
mechanisms behind H-RAS activation with much of this work largely being carried out by the 
Wu lab (Department of Urology, New York University School of Medicine) (Wu, 2005).  
They have utilised the mouse uroplakin II (UPII) promoter, which is expressed in the basal 
layer of the urothelium, within which the stem cell niche resides (Lin et al., 1995). In the first 
instance they targeted expression of a constitutively active rabbit H-RasQ61L to the urothelium 
using this promoter (Zhang et al., 2001).  Their rabbit H-RasQ61L mutant had been previously 
shown to share all the functional characteristics of codon 12 and 13 mutants and to be fully 
capable of transforming culture NIH 3T3 cells (Zhang et al., 2001). 
This induced early onset urothelial hyperplasia, with this hyperplasia progressing to low-
grade non-invasive papillary tumours. Interestingly tumour latency depended on transgene 
number. In the mice that had 1 or 2 copies of the rabbit H-RasQ61L transgene (low-copy), the 
tumour latency was almost 12 months. Histologically by 3-5 months the urothelial layer has 
become hyperplastic (from the usual 3 layers to 6-7 layers).  At 8 months the urothelium 
becomes more hyperplastic, forming areas of nodular hyperplasia.  From 10-26 months of age 
63% of mice developed superficial non-invasive UCC.  These lesions remained non-invasive 
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during the 26-month follow-up period.  In contrast mice harbouring “high-copy” numbers of 
the HRASQ61L RAS transgene (30-48 copies) succumbed to death by 5 months of age. The 
mice had evidence of significantly enlarged bladder and associated bladder outflow 
obstruction (hydronephrosis and hydroureter). Again these tumours were of a papillary non-
invasive histology, with no evidence of muscle invasion or metastases.  
This fits with the human literature in which the Ras oncogene is shown to be frequently 
overexpressed. Quantification of the transcripts in paired tumour and adjacent normal tissue 
identified a 40% overexpression of H-RAS (Vageli et al., 1996). Others have found 
overexpression of HRAS at the protein level in more than 50% of bladder tumours (Dunn et 
al., 1988, Ye et al., 1993). The fact that the bladder tumours in “low-copy” mice developed 
localised, superficial papillary tumours with a much longer latency, suggests, in the absence 
of overexpression, H-Ras, activation requires a secondary event, either genetic or epigenetic, 
to fully induce bladder tumours. These mice have been instrumental in showing the Ras 
pathway activation is sufficient to lead to UCC along the low-grade/non-invasive papillary 
tumourigenesis pathway. They have also suggested that these results indicate urothelial 
hyperplasia may be an important precursor of papillary UCC. 
Subsequently the Wu group found upregulation of the senescent markers Ink4a/Arf in the 
mutant “low copy” HRAS urothelium, without histological evidence of senescence (Mo et al., 
2007).  Surprisingly, when the Ink4a/Arf locus in these mice was genetically knocked out, 
there was no evidence of acceleration of urothelial tumourigenesis. 
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1.7.2. Receptor Tyrosine Kinases 
1.7.2.1. Epidermal Growth Factor Receptor (EGFr) 
 
Epidermal growth factor receptor is overexpressed in 40-60% of human UCC at the mRNA 
and protein levels (Neal and Mellon, 1992). In addition EGFr overexpression has been 
implicated in invasive UCC.  In chemical carcinogen models EGF significantly increased the 
frequency of heterotopically transplanted bladder tumours in rats (Fujimoto et al., 1996). 
The Wu lab targeted expression of functionally active EGFr (demonstrated auto-
phosphorylation and downstream MAPK activation) to the urothelium using the UPII 
promoter (Cheng et al., 2002).  The bladders developed hyperplasia, but did not progress to 
tumour. When combined with activated HRAS transgene there was no synergism in urothelial 
tumourigenesis, again strengthening the redundancy argument since they are both in the same 
signal transduction cascade. Interestingly they found that EGFr could potentiate with the 
SV40 mouse (Simian virus 40, a polyomavirus that interacts SV40 Large T-antigen and SV40 
Small T-antigen, leading to defects in RB and p53) to accelerate CIS conversion into high 
grade UCC. 
 
1.7.2.2. Fibroblast Growth Factor Receptor 3 (FGFR3) 
 
In urothelial tumours, over 70% of low-grade/non-invasive papillary tumours exhibit 
mutations in FGFR3. However only 10-20% of invasive bladder tumours harbour mutations 
in this same locus, leading researchers to postulate that FGFR3 activation is one of the major 
genetic events that lead to low-grade/non-invasive papillary tumours (van Rhijn et al., 2004, 
van Rhijn et al., 2001).  Almost all the mutations have been identified as missense mutations.  
They most frequently involve the receptor’s extracellular loop and affect the cysteine 
residues: either eliminating or creating a cysteine (Wu, 2005). This results in cysteine mis-
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pairing, conformational change/misfolding and the failure of the mutated FGFR3 to exit the 
endoplasmic reticulum.  Additionally some FGFR3 mutations are capable of undergoing 
ligand-independent activation, which lead to autophosphorylation of the intracellular kinase 
domain (Bakkar et al., 2003, Billerey et al., 2001). These mutated receptors exhibit increased 
stability and decreased translocation to the lysosomal degradative pathways (Cho et al., 2004, 
Monsonego-Ornan et al., 2000).  All these factors result in increased and prolonged activation 
of the receptor. 
As indicated earlier HRAS and FGFR3 mutations occur in up to 30% and 70% of clinical 
non-invasive UCC respectively, suggesting that the RTK-Ras pathway is responsible for these 
types of tumours. Recent studies by the Knowles lab (University of Leeds) suggest that 
HRAS and FGFR3 mutations are unlikely to co-exist in the same tumours (Jebar et al., 2005). 
This fits with data from other tumours types such as malignant melanoma, in which 
components from the same signaling pathway are rarely mutated simultaneously (NRAS and 
BRAF in melanoma), presumably since this offers no selective advantage to the tumour cells 
(Takata and Saida, 2006) (Figure 1.6). 
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Figure 1.7: Signalling cascades involved in UCC during FGFR3 and HRAS activation 
FGFR3 and HRAS gene mutation are thought to share the same downstream signalling 
pathway.  FGFR3 consists of 3 extracellular (EC) immunoglobulin-like domains (IgI–III), a 
transmembrane domain (TM), and a cytoplasmic (CP) tyrosine kinase domain (TK1 and 
TK2). Mutations that affect the loop that connects the IgII and IgIII domains account for up to 
50-80% of all mutations, whereas those affecting the TM domain account for up to 15-40% 
and those affecting TK2 account for 5–10%. Loop and TM mutations often create a novel 
cysteine and might be responsible for receptor dimerization (*C–C*) and 
autophosphorylation.  
FGFR3 phosphorylation triggers several signalling cascades, the most predominant of which 
is the Mitogen Activated Protein Kinase (MAPK) pathway.  Phosphorylated FGFR3 can 
activate the phosphatidylinositol 3-kinase (PI3K) and AKT pathway.  Lastly, the activated 
FGFR3 can directly or indirectly (through Janus-family kinases (JAKs)) trigger the signal 
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transducer and activator of transcription (STAT) pathway. The activated FGFR3 can also 
interact directly with proline-rich tyrosine kinase 2 (PYK2), leading to STAT pathway 
activation (Cappellen et al., 1999, Rieger-Christ et al., 2003, van Rhijn et al., 2004, Bakkar et 
al., 2003, van Rhijn et al., 2001, Billerey et al., 2001).  
Mutational activation of HRAS can trigger similar signalling pathways. 
(Adapted from Wu, 2005) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
1.7.2.3. Sprouty (SPRY) 
 
SPRY proteins comprises of a family of well-conserved regulators of RTKs.  SPRY was 
originally identified in Drosophila as an antagonist of fibroblast growth factor (FGF) 
mediated signalling (Hacohen et al., 1998).  Amongst the four mammalian SPRY orthologues 
(SPRY1-4), SPRY2 is the closest to Drosophila SPRY (dSPRY) and extensively studied as a 
RTK modulator.  SPRY2 has been shown to interact with a number of RTK downstream 
signalling components such as Grb2, Raf1, Shp2, c-Cbl and GAP1 (Kim and Bar-Sagi, 2004).  
As a consequence, SPRY2 can regulate both the intensity and duration of RTK mediated 
signalling.  The dSPRY can inhibit both FGF and epidermal growth factor (EGF) mediated 
signalling (Kramer et al., 1999).  However, SPRY2 has been shown to inhibit only FGF 
mediated signalling.  Interestingly, recent evidence indicate that SPRY2 exerts its negative 
and positive regulatory roles on EGF mediated signalling in a distinctive manner by 
interfering the trafficking and degradation of epidermal growth factor receptor (EGFR) (Kim 
and Bar-Sagi, 2004, Rubin et al., 2003, Fong et al., 2003). 
Using OncomineTM (http://www.oncomine.org/geneModule/differential/filterStore.jsp) 
Lindgren and colleagues have demonstrated that in FGFR3 mutant bladder cancer there is a 
downregulation of Sprouty 2 at the mRNA level (p=0.015) (Lindgren et al., 2006). In the 
same study they find that Sprouty2 mRNA levels are downregulated as the disease progresses 
from Grade 1 to 3 (p=0.015).  
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1.7.3. PTEN-PI3K-pAKT 
1.7.3.1. PTEN 
 
The phosphatase and tensin homology (PTEN), located on human chromosome 10, is a lipid 
phosphatase that dephosphorylates phosphoinositide-3,4,5-triphosphate (PI3P). As a result of 
this dephosphorylation, this 55-kDa protein antagonises the activity of PI3 kinase (PI3K), 
preventing it from activating downstream proliferation and survival signals, especially pAKT, 
leading to growth inhibition (Dahia, 2000). 
The PTEN/pAKT pathway has also been implicated in invasive UCC. Evidence suggests that 
restoration of PTEN function induces growth arrest in bladder cancer cell lines deficient in 
PTEN (Tanaka et al., 2000), and inhibition of PI3K may decrease the invasive potential of 
bladder tumours (Wu et al., 2004). 
Also deletion at the PTEN locus (3p, 5q, 10q) is rare in non-invasive, but occur frequently in 
invasive UCC (Puzio-Kuter et al., 2009). The reduction or loss of PTEN protein expression 
was observed in 42% of non-invasive and 94% of advanced UCC. This reduction in PTEN 
correlated with stage and grade (Tsuruta et al., 2006). 
Unfortunately the transgenic models that exist for Pten null mice have been inconsistent, 
possibly due to use of different Pten alleles and promoters, as well as differences in the 
background strains of the mice. 
Yoo and colleagues deleted exon 4-5 of the Pten gene using the Fabp-Cre system (which 
directs recombination in all the cell layers of the urothelium by embryonic day 16.5, as well 
as the intestinal epithelium) and were able to demonstrate urothelial hyperplasia and eventual 
UCC by 13.5 months of age (Yoo et al., 2006). 
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Using a similar model, PTEN null mice (Fabp-Cre Ptenfl/fl) also developed non-invasive UCC 
in 10% of cases, after a long latency (>40 weeks) (Tsuruta et al., 2006).  The long latency and 
low tumour rate could be because of the slow proliferation rate of the urothelium and/or the 
requirement of secondary genetic events for urothelial carcinogenesis. 
More recently Qian and colleagues investigated the role of PTEN in UCC. In their Pten null 
mice (in this mouse exons 4-5 is flanked by the loxP sequences), using the Ksp-Cre promoter 
(expressed in renal tubules, collecting ducts and ureteric bud) they found renal pelvis UCC in 
57% of mice at 12 months (Qian et al., 2009). Interestingly they found upregulation of p-
mTOR in their tumours, suggesting a role for inhibitors of the pathway (i.e. rapamycin) as 
therapeutic agents. 
Surprisingly, another Ptenfl/fl bladder model did not have any urological phenotype when aged 
to 12 months following intravesical administration of the AdenoCre (Puzio-Kuter et al., 
2009).   
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1.7.4. p53 
 
p53 is a nuclear phosphoprotein that acts as a key gatekeeper at the G1/S checkpoint of cell 
cycle progression, integral in controlling urothelial cell growth and maintaining genomic 
stability (Levine, 1997).  Mutation and deletion of the p53 tumour suppressor gene are among 
the most common genetic changes found in human UCC (Wu, 2005). Usually one allele is 
mutated and thus non-functional whilst the other is often deleted, suggesting that p53 is non 
functional in human UCC.  Consistent with these findings, p21 (also known as WAF), an 
important downstream target of p53, is downregulated in the majority of UCCs that harbour 
p53 loss/mutation (Lu et al., 2002, Stein et al., 1998).  Similar to the p53 data, loss of p21 
expression is also associated with disease progression (Stein et al., 1998). 
p53 abnormalities are much more prevalent in invasive UCC (>50%) and precursor CIS 
lesions when compared to the in non-invasive phenotype (Cordon-Cardo et al., 1994, 
Hartmann et al., 2002, Wagner et al., 1995, Spruck et al., 1994, Orntoft and Wolf, 1998). This 
suggests that p53 loss/mutation may be responsible for the formation and progression of 
invasive UCC. 
The commonest site of p53 mutation was found in exon 5 and 8 (George et al., 2007).  90% of 
samples with exon 5 mutations and a substantial proportion of tumours with the exon 8 
mutation demonstrate no nuclear p53 accumulation, suggesting loss of the protein and non-
functionality of the mutation.  The majority of these were point mutations G:C to C:G 
transversions.  Another study found p53 point mutations predominately in codons 280 (Arg to 
Thr) and 285.  These mutations are rare in other epithelial tumours, leading to speculation 
about the role of urothelial specific carcinogens (Feng et al., 2002, Berggren et al., 2001). 
Interestingly the association between smoking and UCC did not differ substantially between 
cases with and without p53 mutations, it was however more strongly associated with CpG 
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G:C-A:T transitions than with other types of mutations (Spruck et al., 1993, Schroeder et al., 
2003).  Patients with p53 mutations have a far higher risk of disease progression and death 
than those without (George et al., 2007, Hartmann et al., 2002, Masters et al., 2003, Cordon-
Cardo, 1998).  
Nuclear accumulation of p53 (a sign of mutation) is significantly associated with a greater 
risk of UCC and decreased overall survival in patients with organ confined disease (Esrig et 
al., 1994).  Their multivariate analysis stratified according to grade, pathological stage and 
lymph node status demonstrated that nuclear p53 accumulation was an independent predictor 
of recurrence free and overall survival (p<0.001) (Esrig et al., 1994).  This is consistent with 
the theory that with models that promote progression of organ confined UCC have abnormal 
nuclear p53 function. 
However, a meta-analysis based on 43 studies comprising 3764 patients with UCC 
demonstrated considerable variation in clinical outcome, different immunohistochemistry 
protocols, patient selection and study design (Schmitz-Drager et al., 2000). 
Murine studies of UCC using the Trp53-knockout have been unsatisfactory since these mice 
develop fatal soft tissue sarcomas and thymic lymphomas by 7 months of age, at which stage 
the urothelium is still normal (Donehower et al., 1992). The heterozygous Trp53-knockout 
mice (which live longer) do not develop any urothelial abnormalities. 
Interestingly a mouse with dominant negative mutation of p53 (lacks DNA binding domain 
but retains the tetramerization domain) targeted to the urothelium using the uroplakin 
promoter develops urothelial hyperplasia and dysplasia without progression to frank 
carcinoma (Gao et al., 2004). Wu and colleagues studied the expression of activated H-Ras 
(again using the UPII promoter) in the absence of p53 (Gao et al., 2004).  They found absence 
of p53 accelerated the formation of the activated H-Ras induced high-grade UCC. However 
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they were unable to prove that these tumours became invasive since the Trp53 null mice died 
of lymphomas by 7 months of age. 
When they repeated the experiment with p53 heterozygous mice they found this acceleration 
was negated and the mouse phenocopied the activated H-Ras mutant.  
Using an adenovirus expressing Cre recombinase delivered directly into the bladder, 
simultaneous p53 and Pten deletion (p53fl/fl Ptenfl/fl) resulted in bladder tumours with 100% 
penetrance at 6 months, with metastasis to local lymph nodes and distant sites, including 
spleen, liver and diaphragm (60% by 4-6 months).  (Puzio-Kuter et al., 2009). The histology 
of these tumours closely resembled that of CIS and invasive tumours found in humans. 
Puzio-Kuter found that their p53fl/fl Ptenfl/fl mice had highly upregulated p-mTOR, and when 
rapamycin was given to these mice tumour regression occurred (Puzio-Kuter et al., 2009, 
Seager et al., 2009). Interestingly when given to mice at the CIS stage, the rapamycin 
abrogated the progression to frank invasive tumourigenesis. 
Currently there are no murine studies looking at the effect of mutant p53 in the formation of 
UCC. 
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1.7.5. p21 WAF/CIP1   
 
The cyclin-dependent kinase inhibitor p21WAF/CIP1 (p21) was originally discovered as a key 
target of the p53 tumour suppressor gene following DNA damage. Induction of p21 by p53 
induced cell cycle arrest by a block in  G1 (Deng et al., 1995).  p21 has been shown to be 
induced in a p53 independent fashion, such as through oxidative stress, cytokines, tumour 
viruses and anti-cancer agents (Abbas and Dutta, 2009).  p21 is also implicated in protection 
from p53-dependent and independent apoptosis (Weiss, 2003, Gartel and Radhakrishnan, 
2005), and its overexpression was  sufficient to drive tumour cells into senescence (Fang et 
al., 1999). Moreover, studies have shown that p21 is key in the induction of senescence 
following treatment with ant-cancer agents (Chang et al., 1999). 
p21 is downregulated in the majority of urothelial carcinomas that have p53 loss/mutation (Lu 
et al., 2002, Stein et al., 1998).  Similar to the literature on p53, loss of p21 expression is also 
associated with a higher recurrence rate and lower survival rate than those tumours with 
maintained p21 expression levels, irrespective of tumour grade and pathological stage (Stein 
et al., 1998).  It was also noted that maintenance of p21 expression appeared to negate the 
effects of p53 alterations on UCC progression (Stein et al., 1998). 
Similarly, Shariat et al demonstrated that positive p21 expression was independently 
associated with reduced UCC recurrence and progression in CIS (with no muscle-invasive 
disease), possibly by p53-independent modulation of p21 (Shariat et al., 2003).   
Although no models of p21 deletion in the urothelium have been published, Yoo and 
colleagues observed upregulation of p21 expression in the urothelium in their PTEN null 
mouse using the urothelial specific Fabp-Cre (Yoo et al., 2006).  In the urothelium of the 
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newborn mice, cell proliferation is initially high, but within days is inhibited by p21 
induction, suggesting a bladder specific compensatory mechanism. 
 
1.7.6. Retinoblastoma (RB) 
 
Recently it has been noticed that patients with germline mutations of RB1 have a higher risk 
of developing epithelial carcinoma, particularly UCC (Fletcher et al., 2004).  Loss of 
heterozygosity (LOH) of RB1 is also prevalent in invasive UCC (Cairns et al., 1991).  Either 
there is a lack of RB expression, or overexpression of a hyper-phosphorylated version of the 
protein (Chatterjee et al., 2004, Logothetis et al., 1992). In these scenarios RB is 
dysfunctional and cannot inhibit E2F family of transcription factors, leading to an increase in 
cell proliferation. Transgenic mice with RB1 ablated in all tissues die embryonically 
(Donehower et al., 1992). 
Mutation of both p53 and RB occur in >50% of invasive UCC, with patients having increased 
rate of recurrence/progression and worse overall survival than patients with single gene 
mutations (Grossman et al., 1998).  Fitting with this, mice with targeted urothelial expression 
of the simian virus 40 (SV40) large T-antigen, which inactivates both p53 and RB together, 
develop CIS and subsequent invasive tumours (Zhang et al., 1999, Grippo and Sandgren, 
2000).  Interestingly the CIS evolved to high-grade papillary UCC before progressing to 
muscle invasive disease.  Whether this is particular to the mouse has yet to be elucidated. 
Recently the Wu lab demonstrated that urothelial specific deletion of both copies of RB (UPII 
Cre) failed to accelerate urothelial proliferation (He et al., 2009). Instead it activated a 
‘failsafe’ signature by profoundly activating the p53 pathway and leading to apoptosis. 
Deletion of p53 in these RB null urothelial cells may therefore remove the tumourigenesis 
barrier.  However this resulted in nuclear atypia and only 2% of mice progressed to non-
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invasive papillary tumours.  Interestingly, mice deficient in both RB and p53 become 
extremely sensitive to chemically induced carcinogenesis (0.01% BBN for 10 weeks) and 
50% developed invasive UCC similar to the human condition. 
This suggests that loss of both p53 and RB is necessary, but insufficient to initiate UCC along 
the invasive pathway (Figure 1.7). It is presumed that other genetic alterations are required to 
trigger invasive UCC. 
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Figure 1.8: Collaborative effects between pRb family proteins and p53 in invasive UCC 
a) Ablation of pRb specifically in urothelium leads to E2F1 over-expression that in turn up-
regulates the p53 pathway and pRb family member p107 along with transcriptional repressor 
E2F4. These compensatory urothelial defences cause urothelial cells to undergo cell-cycle 
arrest and apoptosis. 
b) Additional ablation of p53 in urothelial cells lacking pRb effectively blunted apoptotic 
response, resulting in late-onset hyperplasia and nuclear atypia.  
c) Treatment of urothelial cells lacking both pRb and p53 with bladder carcinogen BBN 
down-regulates p107 and triggers invasive urothelial tumourigenesis. This model emphasizes 
the collaborative effects among pRb family proteins and p53 in invasive urothelial tumour 
initiation. (Adapted from He et al., 2009) 
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1.8 The Wnt signalling pathway 
 
The Wnt pathway is widely conserved throughout many species including C.elegans, 
Drosophila, Xenopus and mammals. The Wnt pathway was originally discovered in 
Drosophila where the gene wingless (wg) demonstrated the ability to influence segment 
polarity during larval development (Nussleinvolhard and Wieschaus, 1980). Murine studies 
identified a gene called Wnt1 (originally named Int-1) which was shown to be a proto-
oncogene in breast tumours induced by the mouse mammary tumour virus (MMTV) (Nusse 
and Varmus, 1982). Further studies went on to show that wingless (wg) was a fly homologue 
of the mouse Wnt1 gene (Rijsewijk et al., 1987). Thus the name Wnt, a compromise of wg, 
from the Drosophilia wingless gene and Int, the mouse homologue.  
The Wnt pathway is now known to control many events during embryonic development, and 
regulates homeostatic self-renewal in a number of adult tissues. As a result, mutations in this 
pathway are associated with the onset of various cancers, due to the influence of the Wnt 
pathway has on processes such as proliferation, motility and cell fate at the cellular level 
(Oving and Clevers, 2002, Polakis, 2000b). Wnt ligands are glycoproteins which interact with 
a seven-transmembrane frizzled cell surface receptor, leading to Wnt pathway activation. 
Three different pathways are believed to be activated upon receptor activation (the Wnt/Ca2+ 
pathway, the non-canonical planar cell polarity pathway and the canonical pathway) (Clevers, 
2006).   
In the planar cell polarity pathway Wnt signalling through frizzled receptors mediates 
asymmetric cytoskeletal organisation and the polarization of cells by inducing modifications 
to the actin cytoskeleton. Two independent pathways, which are initiated by dishevelled, 
trigger the activation of the small GTPases Rho and Rac. Activation of Rho requires Daam-1 
and leads in turn to the activation of the Rho-associated kinase ROCK.  Rac activation is 
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independent of Daam-1 and stimulates JNK activity (Huelsken and Behrens, 2002, Habas and 
Dawid, 2005).  
Wnt signalling via frizzled receptors can also lead to the release of intracellular calcium. 
Frizzled co-receptors, involved in this pathway include Knypek and Ror2. Other intracellular 
second messengers associated with this pathway include heterotrimeric G-proteins, 
phospholipase C (PLC) and protein kinase C (PKC). The exact genes activated by the 
Wnt/Ca2+ pathway are unknown, but NFAT appears to be involved, which is a transcription 
factor regulated by the calcium/calmodulin-dependent protein phosphatase, calcineurin. The 
Wnt/Ca2+ pathway is important for cell adhesion and cell movements during gastrulation 
(Habas and Dawid, 2005, Kohn and Moon, 2005). 
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1.8.1. The Canonical Wnt Signalling Pathway  
 
The canonical Wnt pathway is a ligand dependent system whereby Wnt proteins bind to 
frizzled and LPR family member receptors at the cell surface. This in turn activates 
dishevelled family proteins and ultimately results in an increase in the amount of β-catenin 
that reaches the nucleus (Figure 1.8) (Reya and Clevers, 2005). Consequently β-catenin now 
complexes with TCF/LEF resulting in the transcriptional activation of Wnt target genes. In 
the presence of a Wnt ligand, Frizzled (Fz) proteins cooperate with a single pass transembrane 
molecule called LRP6 to bind the ligand. Upon this binding, the scaffold protein axin 
translocates to the membrane where it interacts with the intracellular tail of LRP5.  This 
results in the disassociation of the destruction complex comprising axin, GSK3β (glycogen 
synthase kinase), CK1 (casein kinase), Apc, and β-catenin (reviewed in Reya and Clevers, 
2005 and Clevers, 2006). Also, by an unknown mechanism, the binding of Wnt to Frizzled 
results in the hyperphosphorylation of Dishevelled (Dsh), which inhibits the activity of  
GSK3β making it  unable to phosphorylate β-catenin (Mao et al., 2001, Yanagawa et al., 
1995).  In its unphosphorylated state, β-catenin is now not recognized by the F-box β-TRCP 
protein, a component of the E3 ubiquitin ligase and therefore is not degraded. Subsequently, 
β-catenin is now free to translocate to the nucleus, where it binds to the N terminus of 
LEF/TCF (lymphoid enhancer factor/T cell factor), and activates transcription of a number of 
Wnt target genes (Behrens et al., 1996, Molenaar et al., 1996, vandeWetering et al., 1997, 
Polakis, 2000b), including c-Myc (He et al., 1998), CD44 (Wielenga et al., 1999),  TCF-1 
(Roose et al., 1999), LEF-1 (Hovanes et al., 2001).  
Therefore, during inappropriate Wnt activation, (caused by Apc/β-catenin mutations), 
activation of key Wnt target genes such as c-Myc lead to uncontrolled bursts in proliferation. 
This once again, serves to highlight the important role that Apc plays as a key ‘gate keeper’ in 
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controlling cell proliferation, particularly in the formation of colorectal cancer (Kinzler and 
Vogelstein, 1996).  
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Figure 1.9: Canonical Wnt Signaling 
a) In the absence of a WNT signal, the level of free intracellular β-catenin is minimised by 
sending it for degradation in the proteasome. Free cytoplasmic β-catenin, which is in 
equilibrium with β-catenin at adherens junctions, is recruited to a 'destruction complex' 
containing APC, axin/conductin and glycogen synthase kinase 3β (GSK3β). GSK3β 
phosphorylates β-catenin, allowing it to be recognized by an SCF complex containing the F-
box protein β-TrCP. Other proteins in the SCF complex catalyse the addition of a 
polyubiquitin chain to β-catenin, allowing β-catenin to be recognized and degraded by the 
proteasome. Consequently, β-catenin cannot reach the nucleus, and cannot co-activate TCF-
responsive genes. Groucho, a corepressor, also prevents the activation of TCF/LEF-
responsive genes in the absence of β-catenin.  
b) In the presence of WNT, its receptor, Frizzled, in complex with LRP6, is activated. This 
leads to a poorly understood signalling cascade in which Dishevelled activates GBP — an 
inhibitor of GSK3β. Consequently, β-catenin cannot be targeted for destruction and is free to 
diffuse into the nucleus, where it acts as a co-activator for TCF/LEF-responsive genes.  
[Adapted from (Fodde et al., 2001)] 
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1.8.2. The Role of Wnt Signalling in Cancer 
 
Germline mutations of the APC gene cause Familial adenomatous polypopsis (FAP).  This is 
an autosomal dominant disease that affects approximately 1/7000 people and is characterised 
by the development of hundreds of colorectal adenomas, often arising by the second decade of 
life (Kinzler and Vogelstein, 1996).  As the patient ages, a small proportion of adenomas 
progress to carcinomas, with 100% of FAP patients developing colorectal cancer by the 
average age of forty years (Sancho et al., 2004). FAP patients can also develop other intestinal 
lesions including gastric fundic gland polyposis, duodenal adenomas, and gastric, pancreatic, 
bilary or distal small intestinal lesions. At much lower frequencies, FAP patients can also 
develop lesions out with the GI tract such as desmoids of the skin, retinal lesions, osteomas 
and brain tumours (Kinzler and Vogelstein, 1996).  
It has also been discovered that mutations in APC occur in the majority of all sporadic 
colorectal tumours (Miyoshi et al., 1992, Powell et al., 1992). Given the high frequency of 
mutations in the APC gene, it has been proposed that APC acts as a key ‘gatekeeper’ gene of 
colonic homeostatsis, importantly controlling colonic epithelial cell proliferation. Therefore a 
mutation in this ‘gatekeeper’ gene results in uncontrolled cellular renewal and proliferation 
(Kinzler and Vogelstein, 1996). Although it is now widely accepted that mutations in APC 
initiate the neoplastic process, it is also known that a sequential series of mutations are 
necessary for tumour progression, 
The ApcMin+ (Multiple Intestinal Neoplasia) mouse was the first murine model to 
phenotypically recapitulate FAP (Moser et al., 1990). The mice demonstrated signs of 
anaemia and were moribund by 120 days. Upon necroscopy, multiple adenomas were 
observed in the small intestine, which occasionally progressed to adenocarcinomas in older 
mice. Each mouse presented with on average 30 intestinal adenomas, hence the name 
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Multiple Intestinal Neoplasia (Moser et al., 1990). The mutation in these adenomas was 
mapped to codon 850 of the murine homologue of the Apc protein, and was  similar to those 
observed in FAP patients (Su et al., 1992). Similar to FAP patients this mutation was 
characterised as a fully penetrant autosomal dominant disorder (Moser et al., 1990).  Despite 
similar germline mutations, FAP patients predominantly have colorectal adenomas which 
routinely progress to invasive adenocarcinoms, in contrast to the small intestinal adenomas 
observed in the ApcMin+ mouse.  This is possibly due to the fact that ApcMin+ mice present with 
a high tumour burden, and as a consequence mice need to be sacrificed before tumours are 
able to progress to adenocarcinomas.  
Outwith colorectal cancer, mutations in the APC gene are much rarer.  In cancer such as 
hepatocellular carcinoma (HCC) Wnt pathway activation is observed through β-catenin 
activating mutations or loss of negative regulators such as Axin or Axin2 (Satoh et al., 2000, 
Giles et al., 2003). Similarly activating/stabilising mutations of β-catenin have been observed 
in melanoma, ovarian carcinomas, childhood hepatoblastomas and medulloblastomas, 
desmoid tumours and non-ductal solid pancreatic tumours (Giles et al., 2003). Interestingly in 
these cancers activating mutations of the Wnt pathways are not thought to be intitating event.  
Zhou et al proposed a role for Wnt signalling in renal carcinoma, since the key renal tumour 
suppressor protein (Von Hippal Lindal) VHL, acts through JADE, an E3 ubiquitin ligase to 
target β-catenin for degradation (Zhou et al., 2005). Therefore,  a mutation in VHL results in 
the stabilisation and activation of the oncogenic β-catenin pathway (Behrens, 2008). This link 
between the pathways explains why FAP patients, with a germline mutation of Apc rarely 
present with renal cell carcinoma, but mice with a renal specific deletion of Apc develop 
cancer similar to those wtih VHL mutations (Sansom et al., 2005). In addition, the promoter 
of the Apc gene is hypermethylated in up to 30% of renal carcinomas (Dulaimi et al., 2004), 
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suggesting Apc loss/reduction may play an important role in the progression of renal 
carcinoma. Indeed using the AhCre transgene which yields sporadic constitutive Cre 
expression within all cell lineages of the kidney, only 1/3 of mice develop renal carcinoma, 
despite showing the presence of small premalignant lesions from 2 months of age (Sansom et 
al., 2005).  This suggests that Apc loss can predispose to renal carcinoma but Apc gene loss 
alone is a very poor iniating event.  In contrast deletion of Apc within the intestinal 
epithelium rapidly leads to a marked ‘crypt-progenitor cell-like’ phenotype (Sansom et al., 
2004) and moreover, deletion of Apc within the LGR5+ stem cell zones leads to adenoma 
formation in as little as 2 weeks, suggesting the importance of the cells that are targeted 
(Barker et al., 2009).  
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1.8.3. The Role of Wnt Signalling in Human UCC 
 
Germline and somatic mutations of APC are found in the majority of colorectal cancers 
(Kinzler et al., 1991, Cottrell et al., 1992, Rubinfeld et al., 1993). However, in the case of 
bladder carcinoma, controversy surrounds the occurrence of somatic mutations in key 
components of the pathway; APC (Miyamoto et al., 1996, Bohm et al., 1997, Stoehr et al., 
2002, Urakami et al., 2006a) and β-catenin (Burger et al., 2008, Shiina et al., 2002, Shiina et 
al., 2001).  Miyamoto and colleagues found LOH of the APC locus in only 1 of 16 (6%) of 
UCCs (Miyamoto et al., 1996).  However another study reported LOH for the APC locus in 
50% of the 30 tumours (Bohm et al., 1997).  In a larger study Stoehr and colleagues found 
LOH in 10% of 72 tumours, but no APC mutations in 22 tumours and 4 cell lines, apart from 
a common SNP at codon 1493.  All of these studies, however included both non-invasive and 
invasive tumours, and utilised them as a single entity.  Recent human UCC sequencing by the 
Sanger institute in Cambridge has revealed APC mutation in 11 out of 93 (12%) samples 
(http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=bycancer&ln=APC&sn=urinary_
tract&ss=bladder).  
Many of these studies have demonstrated immunohistochemical upregulation of β-catenin, the 
key protein in this pathway (Kashibuchi et al., 2006, Nakopoulou et al., 2000, Shimazui et al., 
1996, Zhu et al., 2000, Garcia et al., 2000).  Urakami and colleagues showed that CpG 
hypermethylation of Wnt inhibitory factor-1 (Wif-1) was a frequent event in bladder 
tumourigenesis (Urakami et al., 2006b).  Most recently Kastritis and colleagues demonstrated 
APC missense (13%) and frameshift (3%) deletions adjacent to the β-catenin binding sites in 
bladder tumours (Kastritis et al., 2009).  They found either APC mutations or β-catenin 
accumulation resulted in shorter disease free interval, and a shorter disease specific survival in 
multivariate analysis.  Similarly, epigenetic silencing of the four secreted frizzled receptor 
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proteins (SFRP), antagonists of the Wnt signalling pathway, has been demonstrated as an 
independent predictor of invasive bladder cancer (Marsit et al., 2005).  In a cohort of 355 
patients, a linear relationship between the magnitude of the risk of invasive disease and the 
number of SFRP genes methylated was observed (p<0.0004) with a subsequent reduction in 
overall survival (p<0.0003). Therefore these studies suggest a key role of deregulation of Wnt 
signalling in bladder cancer, a finding that I tested in this thesis. 
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1.9. KEGG Pathway of UCC 
KEGG (Kyoto Encyclopaedia for Genes and Genome) is a bioinformatics resource that has 
been developed to attempt to link the common genetic mutations and pathways occurring in 
human cancer including UCC.  The pathways for UCC are reproduced below: 
 
Figure 1.10: KEGG Pathway of UCC 
(http://www.genome.jp/kegg/pathway/hsa/hsa05219.html) 
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1.10. Research in Progress and Outstanding Research Questions 
 
The currently available models have provided researchers with a wealth of information 
regarding potential molecular mechanisms and pathways involved in bladder cancer.  
However, many limitations still exist.  No model as yet demonstrated metastasis to the 
skeletal system.  A transgenic mouse that demonstrates these would be invaluable in 
preclinical therapeutic models.  Why spontaneous osseous lesions have not been achieved 
remains to be elucidated, but may be due to a variety of reasons including the murine platform 
representing fundamental pathophysiological differences (e.g. pelvic venous drainage), the 
inability to accurately detect the metastasis or whether the genetic defects I created in our 
current models are not sufficient to initiate bone metastasis.   
As I have described there are a paucity of publications regarding therapeutic trials in murine 
models.  As further novel genes and markers are identified in the human bladder 
carcinogenesis, it is essential that we base our murine models on these findings.  Newer 
models will mimic human bladder tumourigenesis more closely and will offer attractive 
platforms for trials of novel agents. 
The in vivo imaging of tumours has revolutionised the way researchers now manipulate 
murine models of cancer.  The technology will allow one to follow disease progression as 
well as the effects of therapeutic interventions in a model system comparable to that of 
humans (Weissleder, 2002).  The two most widely available imaging modalities currently are 
bioluminescent enzyme firefly luciferase and green fluorescent protein (GFP).  GFP provides 
the benefit that one can directly monitor cells down to the single cell level, whilst luciferase 
only allows one to view derived pseudo-layered images.  GFP allow does not require injection 
of a substrate.  Despite this luciferase is much more sensitive and allows one to 
simultaneously monitor multiple mice (whereas GFP requires multiple excitation sources for 
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multiple mice) (Massoud and Gambhir, 2003, Choy et al., 2003). One of the most applied 
techniques uses bioluminescent imaging to noninvasively monitor the growth of luciferase-
expressing carcinoma cells in vivo. In this thesis I plan to utilise both ultrasound and 
fluorescence based imaging techniques to image bladder tumours and assess their response to 
treatment. 
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1.11. Thesis Aims 
 
• To investigate whether Wnt signaling is sufficient to drive tumourigenesis within the 
bladder urothelium 
 
• To investigate the role of Wnt signaling within the bladder urothelium as a progressor 
mutation of UCC in the background of mutations to other key oncogenic/tumour 
suppressors (PTEN, Ras, p21, FGFR3) 
 
• To utilise the above transgenic mice to develop better models of UCC 
 
 
Figure 1.11: Outline of research 
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Chapter 2:  Material and Methods 
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2.0. Material and Methods 
2.1. Statement of Contribution 
• Choosing which mice were to be mated to give genotypes required (animal staff 
physically set up matings, carried out weanings and tail tippings) 
• Tumour surveillance of mice (3 x weekly) 
• Drug treatment of all mice 
• Harvesting of organs 
• Imaging of organs via US and OV100 
• All immunohistochemistry 
• All counting/scoring (double scored with Lukram Babloo Singh LBS) 
• Extracting DNA and carrying out all PCR reactions at least once for each genotype 
(using published protocols for each mouse strain).  When reaction was confirmed as 
working, gel product sent to Transnetyx, IncTM (TN, USA) to allow them to sequence 
product and develop qPCR based genotyping assay to outsource any subsequent 
genotyping. 
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2.2. Generation of Mice colonies 
 
Mouse Experiments: All experiments were performed under the UK Home Office guidelines 
(project license 60/3947, personal license 60/11372). All mice were of a mixed background 
(derived predominantly from FVB/N [H-RasQ61L, Fgfr3 K644E, Fgfr3 K644M] and C57BL/6 
[Apcfl/+, β-catenin exon3/+, GSK3αβfl/fl, K-RasG12D/+, p21-/+, Ptenfl/+ and Z/EGFP] strains) mice) 
and littermates were used as control mice. All mice were maintained under non-barrier 
conditions and given a standard diet (Harlan) and water ad libitum.  The Biological services 
department at the Beatson Institute provided animal husbandry including setting up matings, 
weaning pups, and tail tipping for genotyping. 
The following cre were used: Uroplakin II (UroIICRE+) (Zhang et al., 1999) and AhCreERT 
mice (Kemp et al., 2004). 
They were intercrossed with the following alleles in this thesis: Apcfl/+ (Shibata et al., 1997), 
β-cateninexon3/+ (Harada et al., 1999), Fgfr3 K644E and Fgfr3 K644M (Iwata et al., 2000, 
Iwata et al., 2001), GSK3αβfl/fl (Patel et al., 2008, MacAulay et al., 2007), the rabbit H-RasQ61L 
transgene (Zhang et al., 2001), K-Ras G12D/+ (Jackson et al., 2001), p21-/+ (Deng et al., 1995), 
Ptenfl/+ (Lesche et al., 2002) and the Z/EGFP allele (Novak et al., 2000) (Table 2.1). 
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Transgene Description Reference 
UroIICRE+ Uroplakin II is a protein expressed throughout the 
urothelial layers in mice. The 3.6-kb 5’-upstream 
sequence of mouse Uroplakin II promoter has 
been reported to successfully drive the expression 
of proteins including SV40 large T antigen and H-
Ras.  Previous studies (as well as ours) have 
shown that the UroIICRE+ mice exhibit bladder 
specific recombination. 
(Zhang et al., 1999) 
Ah CreERT This is the cytochrome p450 inducible AhCreERT 
transgene. Following administration of both β-
napthoflavone and tamoxifen, this yields cre-
mediated recombination within the urothelium of 
the bladder (as well as the intestine and liver). 
(Kemp et al., 2004) 
Apcfl/+ loxP sites have been inserted into the introns 
around Apc exon 14, inducing a frameshift 
mutation at codon 580, resulting in the mutant 
allele (Apc 580S) being introduced in a Cre specific 
manner. 
(Shibata et al., 1997) 
β-cateninexon3/+ In this transgene the β-catenin gene has its exon3 
flanked by loxP sequences. On addition of Cre 
recombinase, exon3 is deleted. As this exon 
contains the residues that are phosphorylated by 
GSK3β, leading to β-catenin degradation, β-
catenin will therefore accumulate to drive Wnt 
signalling. 
(Harada et al., 1999) 
Fgfr3 K644E 
and K644M 
Both lines carry a neomycin resistant gene (neo) 
flanked by loxP sites in the intron approximate to 
the exon with the K644 mutations. This neo 
insertion is known to suppress the expression of 
Fgfr3 mutant allele in the absence of Cre 
recombination. In the presence of Cre, the neo 
gene is excised allowing expression of the mutant 
Fgfr3 protein, with a pattern and protein 
expression level similar to those of the age 
matched wildtype 
(Iwata et al., 2000, 
Iwata et al., 2001) 
GSK3αβfl/fl GSK3αfl/fl were generated with loxP sites flanking 
exon2 (by homologous recombination).  Cre 
recombination results in a loss of the protein. 
GSK3βfl/fl were generated with loxP sites flanking 
exon2 (by homologous recombination).  Cre 
recombination results in transcription of a non-
functional protein form of GSK3β. 
 
(Patel et al., 2008, 
MacAulay et al., 2007) 
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H-RasQ61L Constitutively active rabbit H-RasQ61L mutant had 
been previously shown to share all the functional 
characteristics of codon 12 and 13 mutants and to 
be fully capable of transforming culture NIH 3T3 
cells.  Transgene drive by UPII promoter. Low 
copy number (2 copies) used in this thesis 
(Zhang et al., 2001) 
K-Ras G12D/+ A Lox–Stop–Lox K-Ras conditional mouse strain, 
in which expression of oncogenic K-Ras is 
controlled by a removable transcriptional 
termination Stop element.  The endogenous K-Ras 
locus is targeted in the LSL- K-Ras G12D strain 
and, therefore, endogenous levels of oncogenic K-
Ras G12D protein are expressed following 
removal of the Stop element.  
(Jackson et al., 2001) 
p21-/+ This targeting construct p21neo was used to delete 
exon 2 of the p21CIP1/WAP1 gene. This exon 
encodes about 90% of coding sequence of the 
p21CIP1/WAP1 protein, and Cre recombination 
results in loss of the protein. 
(Deng et al., 1995) 
Ptenfl/+ Conditional inactivatable Pten allele (where exon 
5 is flanked by loxP sites).  This encodes for the 
phosphatase domain of PTEN in which many 
tumor-associated mutations have been detected. 
(Lesche et al., 2002) 
Z/EGFP The Z/EGFP transgene results in the expression of 
β-galactosidase by most tissues via a β-geo insert, 
which is flanked by loxP sites.  The presence of 
Cre recombinase results in the excision of the β-
geo, activating the constitutive expression of GFP. 
(Novak et al., 2000) 
 
Table 2.1: Description of transgenes used in this thesis 
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2.2.1. Mouse experiments for Chapter 3 (β-Catenin activation synergises with PTEN loss 
to cause bladder cancer formation) 
 
To achieve urothelial specific expression of activated β-catenin and PTEN loss, these mice 
were interbred with mice carrying the uroplakin II (UroIICRE+) Cre transgene to generate the 
following cohorts UroIICRE+ β-catenin+/+, UroIICRE+ β-cateninexon3/+ and UroIICRE+ β-
cateninexon3/exon3, UroIICRE+ Ptenfl/+, UroIICRE+ Ptenfl/fl, UroIICRE+ β-cateninexon3/+ Ptenfl/+, 
UroIICRE+ β-cateninexon3/exon3 Ptenfl/+, UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl, β-cateninexon3/+ 
Ptenfl/fl and UroIICRE+ β-cateninexon3/+ Ptenfl/+.  
I also bred the AhCreERT mice to Apcfl/fl, Ptenfl/fl and GSK3αβfl/fl mice to generate the 
following cohorts AhCreERT Apcfl/fl, AhCreERT Apc fl/fl Ptenfl/fl and AhCreERT GSK3αβfl/fl. 
For Cre induction, AhCreERT mice were given 3 injections intra-peritoneally (IP) of 80mg/kg 
β-napthoflavone and Tamoxifen in a single day, which yields nearly 100% constitutive 
recombination in the murine small intestine (Marsh et al., 2008).  
Approximately a quarter of each cohort were also bred with the Z/EGFP allele (Novak et al., 
2000). This is a double reporter mouse line that expressed enhanced GFP upon Cre-mediated 
recombination. 
Tumourigenic cohorts (n>20 for each genotype) were aged, and examined three times a week 
by myself for signs of urinary tract disease. These included blood in the urine, hunching, and 
swollen kidneys; which was investigated through scruffing the mouse and gently feeling for 
an enlarged kidney, renal pelvis or urinary bladder that was indicative of a tumour.  This was 
the criterion for sacrifice of the animal.  Metastatic disease was assessed both at a 
macroscopic levels in organs (lung, liver, spleen, diaphragm and local lymph nodes) and at a 
microscopic level by looking at multiple sections through the organ of interest. 
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2.2.2. Mouse experiments for Chapter 4 (β-Catenin activation synergises with Ras 
activation to cause bladder cancer formation) 
 
Uroplakin II Cre mouse (UroIICRE+) mice were intercrossed with mice harbouring Z/EGFP, 
β-catenin exon3/+, K-Ras G12D/+, the H-RasQ61L transgene and p21-/- in the following 
combinations UroIICRE+K-RasG12D/+, H-RasQ61L, UroIICRE+ β-cateninexon3/exon3 K-RasG12D/+, 
UroIICRE+ β-cateninexon3/exon3 H-RasQ61L, UroIICRE+ p21-/- and UroIICRE+ β-cateninexon3/exon3 
p21-/-. 
Approximately a quarter of mice from each cohort were also bred with the Z/EGFP allele 
carrying mice.   
Mice were assessed as per 2.2.1. 
 
2.2.3. Mouse experiments for Chapter 5 (The FGFR3 mutation cooperates with K-Ras 
and β-catenin mutations to promote skin and lung but not bladder tumour formation) 
 
UroIICre+ mice were bred to lines carrying Fgfr3 K644E, Fgfr3 K644M, K-Ras G12D/+ and β-
catenin exon3/+ to generate the following cohorts UroIICre+Fgfr3+/K644E and 
UroIICre+Fgfr3+/K644M UroIICre+Fgfr3+/K644EK-RasG12D/+ and UroIICre+Fgfr3+/K644Eβ-
cateninexon3/+. 
Approximately a quarter of mice from each cohort were also bred with the Z/EGFP allele 
carrying mice. 
Mice were assessed as per 2.2.1.  
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2.3. Tissue isolation 
 
For the analysis of urothelial cell carcinoma (UCC) cohorts, at the appropriate time, mice 
were culled and both kidneys, ureters and the urinary bladder were removed and fixed in 4% 
formalin, overnight at 4oC for no more than 24 hours before processing and were then paraffin 
embedded. For senescence associated β-galactosidase staining, urinary bladder and kidney 
were placed on a cork disk and covered in OCT fixative before being submerged into liquid 
nitrogen.  
When urinary bladders were excised they were all emptied of urine. All bladders were 
processed and cut in the same manner by a single histology technician (Mr. Colin Nixon) to 
aid standardisation. 
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2.4. Genotyping of mice 
 
When I started at the Beatson, genotyping was carried out in-house by the Genotyping 
facility.  In 2009 this was outsourced to TransnetyxTM (TN, USA) who genotype based on real 
time PCR techniques. 
  
2.4.1. DNA Extraction from tails 
 
DNA was extracted from tails using the Purgene DNA Extraction kit.  Tails were lysed 
overnight in 500µl of cell lysis solution (Puregene) and 10µl of proteinase K (20mg/ml, 
Sigma), shaken at 37ºC.   Tails were then left to cool at room temperature; 200µl of protein 
precipitation solution (Puregene) was added to each tube.  These were vortexed and 
centrifuged at top speed for 5 minutes in a microfuge. 
The supernatant was removed into a clean tube containing 500µl of isopropanol, vortexed and 
centrifuged at top speed for 5 minutes.   The supernatant was poured off and the DNA pellet 
was left to dry overnight.  DNA was resuspended in 500µl DNA hydration solution 
(Puregene). 
 
2.4.2. Genotyping of Mice via PCR 
 
Initially all genotyping of mice was done by genomic PCR (Polymerase Chain Reaction) from 
DNA extracted from tails (2.2.1) by the in-house genotyping facility.  All PCR were done in 
50µl volumes using 2.5µl of the tail DNA preparation.  The groups that created the mice 
developed these protocols. 
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Apcfl PCR Protocol 
PCR mix 
       µl 
5x Colorless GoTaq Flexi Buffer*  10 
MgCl2 (25mM)    5 
dNTPs  (10mM)    0.4 
Primer  (100µM)    0.2 (of each) 
Go Taq*      0.2 
H2O to final volume of 47.5 µl 
*GoTaq Flexi DNA Polymerase from Promega.  
 
Primers 
APC F = 5’ GTT  CTG TAT CAT GGA AAG ATA GGT GGT C 3’ 
APC R = 5’ CAC TCA AAA CGC TTT TGA GGG TTG 3’ 
 
PCR Program: 95°C, 3min (95°C, 30s; 60°C, 30s; 72°C 1min) 30 72°C, 5min. 4°C, hold. 
PCR products were run on a 2% gel. 
Bands FLOX = 314bp 
WT = 226bp  
 
 
Figure 2.1: Apcfl PCR 
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β-cateninexon3 PCR Protocol 
PCR mix 
       µl 
5x Colorless GoTaq Flexi Buffer*  10 
MgCl2 (25mM)    5 
dNTPs  (10mM)    0.4 
Primer  (100µM)    0.2 (of each) 
Go Taq*      0.2 
H2O to final volume of 47.5 µl 
*GoTaq Flexi DNA Polymerase from Promega.  
 
Primers  
β-catenin act F = 5’ CTG CGT GGA CAA TGG CTA CT 3’ 
β-catenin act R = 5’ TCC ATC AGG TCA GCT GTA AAA A 3’ 
 
PCR Program: 94°C, 2.5min (94°C, 30s; 60°C, 30s; 72°C 1min) 34 72°C, 10min. 4°C, hold. 
Products run on a 2% gel 
Bands WT = 324bp 
Dominant stable = ~500bp 
 
Figure 2.2: β-cateninexon3 PCR 
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Cre PCR Protocol 
PCR mix 
       µl 
5x Colorless GoTaq Flexi Buffer*  10 
MgCl2 (25mM)    5 
dNTPs  (10mM)    0.4 
Primer  (100µM)    0.2 (of each) 
Go Taq*      0.2 
H2O to final volume of 47.5 µl 
*GoTaq Flexi DNA Polymerase from Promega.  
 
Primers 
CRE F = 5’ TGA CCG TAC ACC AAA ATT TG 3’ 
CRE R = 5’ ATT GCC CCT GTT TCA CTA TC 3’ 
 
PCR Program: 95°C, 3min (95°C, 30s; 55°C, 30s; 72°C 1min) 30,72°C, 5min. 15°C, hold. 
Bands CRE = 1000bp 
 
Figure 2.3: Cre PCR 
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Fgfr3 K644 Protocol  
PCR Mix 
    µl 
Buffer   5 
MgCl2 (50mM) 2.5 
dNTPs  (10mM) 0.4 
Primer  (100µM) 0.1 (of each) 
Platinum Taq  0.2 
H2O to final volume of  47.5 
 
Primers 
F = 5’ GGG TGA TGC TTT GCC TGA GC 3’  
R = 5’ TTC AGA TCT CCC TAC CCC CAT 3’ 
 
PCR Program: 94°C, 3min (94°C, 1min; 60°C, 1min; 72°C 1min) 30, 72°C, 7min. 15°C, hold. 
PCR product was digested with BbsI 
Bands WT = Double band of ~120bp  
+/K644 = Two bands of ~120bp and 350bp 
K644/K644 =Band of 350bp only 
 
Figure 2.4: Fgfr3 K644 PCR 
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GSK3α PCR Protocol 
PCR Mix 
    µl 
Buffer   10 
MgCl2 (50mM) 5 
dNTPs  (10mM) 0.4 
Primer  (100µM) 0.2 (of each) 
Go Taq   0.2 
H2O to final volume of  47.5 
 
Primers 
GSK3α F = 5’ CCC CCA CCA AGT GAT TTC ACT GCT A 3’  
GSK3α R = 5’ AAC ATG AAA TTC CGG GCT CCA ACT CTA T 3’  
 
PCR Program: 94°C 2mins (94°C, 30s;56°C, 30s; 68°C 1min)35, 68°C 7 min; 15°C, hold. 
Bands (NULL = 250bp) 
WT = 600bp 
FLOX= 750bp  
 
 
Figure 2.5: GSK3α PCR 
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GSK3β PCR Protocol 
PCR Mix 
    µl 
Buffer   10 
MgCl2 (50mM) 5 
dNTPs  (10mM) 0.4 
Primer  (100µM) 0.2 (of each) 
Go Taq   0.2 
H2O to final volume of  47.5 
 
Primers 
GSK3βfl F = 5’ GGG GCA ACC TTA ATT TCA TT 3’ 
GSK3βfl R = 5’ TCT GGG CTA TAG CTA TCT AGT AAC G 3’ 
 
PCR Program: 94°C 2mins (94°C, 30s;56.5°C, 30s; 68°C 1min)35, 68°C 7 min; 15°C, hold. 
Bands  WT = 600bp 
FLOX= 1100bp  
 
Figure 2.6: GSK3β PCR 
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Rabbit H-RasQ61L Transgene PCR Protocol 
PCR mix 
       µl 
5x Colorless GoTaq Flexi Buffer*  10 
MgCl2 (25mM)    5 
dNTPs  (10mM)    0.4 
Primer  (100µM)    0.2 (of each) 
Go Taq*      0.2 
H2O to final volume of 47.5 µl 
*GoTaq Flexi DNA Polymerase from Promega.  
 
Primers 
RABBIT HRAS F =  5’  CGGCGGTGTAGGCAAGAGCGC 3’ 
RABBIT HRAS R =  5’ TCTTGGCCGAGGTCTCGATA 3’ 
 
PCR Program: 94°C, 5min (94°C, 1 min; 64°C, 30s; 72°C 1min)35, 72°C, 8min. 4°C, hold. 
Bands RABBIT HRAS = ~500bp 
Only HET should have a band here 
 
Figure 2.7: Rabbit H-RasQ61L PCR 
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K-Ras G12D PCR Protocol (Split PCR) 
PCR Mix 
    µl 
Buffer   5 
MgCl2 (50mM) 2.5 
dNTPs  (10mM) 0.4 
Primer  (100µM) 0.1 (of each) 
Platinum Taq  0.2 
H2O to final volume of  47.5 
 
Note: This is a duplex PCR  
WT Reaction use primers KRasG12D WT and KRasG12D Universal 
LSL Reaction use primers KRasG12D Mut and KRasG12D Universal 
 
Primers 
KRasG12D WT = 5’ GTC GAC AAG CTC ATG CGG GTG 3’ 
KRasG12D Universal = 5’ CCT TTA CAA GCG CAC GCA GAC TGT AGA 3’ 
KRasG12D Mut = 5’ AGC TAG CCA CCA TGG CTT GAG TAA GTC TGC A 3’ 
 
PCR Program: 94°C 3min (94°C, 30s; 60°C, 1min 30; 72°C 1min) 35, 72°C, 5min. 4°C hold. 
Bands WT = 500bp 
LSL = 550bp  
 
Figure 2.8: K-Ras G12D PCR 
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Ptenfl PCR Protocol 
PCR Mix 
    µl 
Buffer   5 
MgCl2 (50mM) 2.5 
dNTPs  (10mM) 0.4 
Primer  (100µM) 0.1 (of each) 
Platinum Taq  0.2 
H2O to final volume of  47.5 
 
Primers 
PTEN Fl F = 5’ CTC CTC TAC TCC ATT CTT CCC 3’ 
PTEN Fl R = 5’ ACT CCC ACC AAT GAA CAA AC 3’ 
 
PCR Program: 95°C, 2min 30s (94°C, 1min; 58°C, 1min; 72°C 1min)35, 72°C, 10min. 15°C, 
hold. 
Bands WT = 228bp 
Flox = 335bp  
 
Figure 2.9: Pten PCR 
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p21 PCR Protocol (Split PCR) 
PCR Mix 
    µl 
Buffer   5 
MgCl2 (50mM) 2.5 
dNTPs  (10mM) 0.4 
Primer  (100µM) 0.1 (of each) 
Platinum Taq  0.2 
H2O to final volume of  47.5 
 
Note: This is a duplex PCR  
WT Reaction use primers p21F and p21R 
Mutant Reaction use primers p21-5 and R1N-1A 
 
Primers 
P21 F = 5’ TCT TGT GTT TCA GCC ACA GGC  3’ 
P21 R = 5’ TGT CAG GCT GGT CTG CCT CC 3’ 
P21-5. =  5’ ATT TTC CAG GGA TCT GAC TC 3’ 
R1N-1A =  5’ CCA GAC TGC CTT GGG AAA AGC 3’ 
PCR Program: 95ºC, 2min (95ºC, 30s; 59ºC, 30s; 72ºC, 1min) 35, 72ºC, 3min. 4ºC hold. 
Bands WT = 430bp 
NULL = 150bp  
 
Figure 2.10: p21 PCR 
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Z/EGFP (GFP) PCR Protocol 
PCR Mix 
       µl 
5x Colorless GoTaq Flexi Buffer*  10 
MgCl2 (25mM)    5 
dNTPs  (10mM)    0.4 
Primer  (100µM)    0.2 (of each) 
Go Taq*      0.2 
H2O to final volume of 47.5 µl 
 
*GoTaq Flexi DNA Polymerase from Promega.  
 
Primers 
Bry-GFP F = 5’ ACG TAA ACG GCC ACA AGT TC 3’ 
Bry-GFP R = 5’ AAG TCG TGC TGC TTC ATG TG 3’ 
 
PCR Program: 95°C, 3min (95°C, 30s; 58°C, 45s; 72°C 1min) 40 72°C, 5min. 4°C, hold. 
 
Band GFP = 187bp 
 
 
Figure 2.11: Z/EGFP PCR 
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2.4.3. Summary of PCR reactions 
 
PCR Primer Sequences 
(5' to 3') 
PCR Program Expected 
Products 
Apc Flox APC F = GTT  CTG TAT CAT GGA AAG ATA GGT GGT C 
APC R = CAC TCA AAA CGC TTT TGA GGG TTG ATT C 
 
95°C, 3min (95°C, 30s; 
60°C, 30s; 72°C 1min) 30 
72°C, 5min. 4°C, hold. 
FLOX = 
314bp 
WT = 
226bp 
 
β-catenin 
exon3 
β-catenin F = CTG CGT GGA CAA TGG CTA CT 
β-catenin R = AAA AAT GTC GAC TGG ACT ACC T 
94°C, 2.5min (94°C, 30s; 
60°C, 30s; 72°C 1min) 34 
72°C, 10min. 4°C, hold. 
WT = 
324bp 
Dominant 
stable = 
~500bp 
Cre  CRE F  = TGA CCG TAC ACC AAA ATT TG 
CRE R = ATT GCC CCT GTT TCA CTA TC 
 
95°C, 3min (95°C, 30s; 
55°C, 30s; 72°C 1min) 30 
72°C, 5min. 15°C, hold. 
 
CRE = 
~1000bp 
 
FGFR3 
K644 
F = GGG TGA TGC TTT GCC TGA GC   
R = TTC AGA TCT CCC TAC CCC CAT 
 
94°C, 3min (94°C, 1min; 
60°C, 1min; 72°C 1min) 
30 
72°C, 7min. 15°C, hold. 
 
Double 
band of 
~120bp  
+/K644 = 
Two bands 
of ~120bp 
and 350bp 
K644/K644 
=Band of 
350bp only 
GSK3α 
null 
GSK3α F = CCC CCA CCA AGT GAT TTC ACT GCT A  
GSK3α R = AAC ATG AAA TTC CGG GCT CCA ACT CTA 
T  
 
94°C 2mins (94°C, 30s; 
56°C, 30s; 68°C 1min)35 
68°C 7 min 
WT = 
600bp 
NULL = 
250bp 
GSK3βfl  GSK3βflF = GGG GCA ACC TTA ATT TCA TT 
GSK3βflR = TCT GGG CTA TAG CTA TCT AGT AAC G 
 
94°C, 2min 30s (94°C, 
30s; 56.5°C, 30s; 68°C, 
1min, 25s) 30  
68°C, 7min.  
FLOX = 
1100bp 
WT = 
895bp 
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Rabbit H-
Rqw 
Transgene 
RABBIT HRAS F = CGGCGGTGTAGGCAAGAGCGC 
RABBIT HRAS R = TCTTGGCCGAGGTCTCGATA 
 
94°C, 5min (94°C, 1 min; 
64°C, 30s; 72°C 1min) for 
35 cycles, 
72°C, 8min. 4°C, hold. 
 
RABBIT 
HRAS = 
~500bp 
 
K-RasG12D 
(Duplex 
PCR) 
 
KRasG12D WT = GTC GAC AAG CTC ATG CGG G 
KRasG12D Universal = CGC AGA CTG TAG AGC AGC G 
KRasG12D Mut = CCA TGG CTT GAG TAA GTC TGC 
 
94ºC, 3min (94ºC, 30s; 
60ºC, 1.5min; 72ºC, 1min) 
35 
72ºC, 5min. 4ºC hold. 
WT = 
~500bp 
LSL = 
~550bp 
p21 Null 
(Duplex 
PCR) 
 
P21 F = TCT TGT GTT TCA GCC ACA GGC  
P21 R = TGT CAG GCT GGT CTG CCT CC  
(WT PCR) 
95ºC, 2min (95ºC, 30s; 
59ºC, 30s; 72ºC, 1min) 35  
72ºC, 3min. 4ºC hold. 
WT = 
430bp  
 
 P21-5. =  ATT TTC CAG GGA TCT GAC TC 3’ 
R1N-1A =  CCA GAC TGC CTT GGG AAA AGC 3’ 
(P21 interrupted PCR) 
95ºC, 2min (95ºC, 30s; 
59ºC, 30s; 72ºC, 1min) 35  
72ºC, 3min. 4ºC hold. 
NULL = 
150bp  
 
Pten Flox PTEN F = CTC CTC TAC TCC ATT CTT CCC 
PTEN-R = ACT CCC ACC AAT GAA CAA AC 
 
95°C, 2min 30s (94°C, 
1min; 58°C, 1min; 72°C 
1min) 35  
72°C, 10min. 15°C, hold. 
WT = 
228bp 
Flox = 
335bp 
Z/EGFP GFP F = ACG TAA ACG GCC ACA AGT TC  
GFP R = AAG TCG TGC TGC TTC ATG TG 
 
95°C, 3min (95°C, 30s; 
58°C, 45s; 72°C 1min) 
40 72°C, 5min. 4°C, 
hold. 
 
GFP = 
187bp 
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2.5. Rapamycin Treatment 
 
Mice were also treated with either Rapamycin (LC laboratories, Woburn, MA) or vehicle 
treatment. This was provided once daily via intraperitoneal (i.p.) at 10mg/kg in vivo for 4 
weeks. The i.p. solution was prepared as an aqueous solution with a final concentration of 4% 
ethanol, 5% polyethylene glycol and 5% Tween 80 immediately before injection (Namba et 
al., 2006). 
 
2.6. Assaying urothelial lesions in vivo 
 
At each indicated time point, a minimum of three animals were killed and the urinary bladder 
was removed.  Urine was removed and the bladder was fixed overnight in 4% formalin before 
processing.  Haematoxylin and Eosin (H&E) stained sections were made and the number of 
lesions were counted using the Olympus BX51 microscope.  At least 3 sections were counted 
from each mouse and the number of lesions was averaged over these 3 slides to give an 
average lesion count for that mouse. For each genotype, 3 age-matched mice were used.  
Statistics (Mann Whitney tests) were performed using Minitab v.15.  In Boxplots the thick bar 
represents median, and the box represents the inter-quartile range. 
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2.6.1. Assaying proliferation in vivo  
 
In order to examine levels of proliferation mice were injected with 250ul of 
bromodeoxyuridine (BrdU) (Amersham) two hours prior to being sacrificed (50mg/kg). 
Immunohistochemical staining for BrdU was then performed using an anti-BrdU antibody 
(BD 1:50). At least 3 mice were used for each genotype and timepoint. To examine levels of 
proliferation, following a two-hour BrdU pulse chase, total numbers of BrdU positive cells 
per lesion/tumour were counted.  
To quantify levels of proliferation between different cohorts of mice, at least 3 mice of each 
genotype were injected with BrdU two hours prior to being sacrificed. BrdU 
immunohistochemistry was then performed on paraffin embedded urinary bladder sections of 
these mice.  
Statistics (Mann Whitney tests) were performed using Minitab v.15.  In Boxplots the thick bar 
represents median, and the box represents the inter-quartile range. 
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2.7. Immunohistochemistry 
 
2.7.1. Immunohistochemistry on frozen sections: 
 
Senescence associated β-galactosidase: 
Frozen sections of either kidney or urinary bladder were cut into 3µm sections on Poly-L-
lysine slides (Sigma). Sections were then thawed at room temperature for 30 minutes. The 
senescence β-galactosidase staining kit from Cell signalling (# 9860) was used. Slides were 
then fixed with 1x fixative solution from the kit for 10 minutes at room temperature. Slides 
were then washed 2x in dH20. A 1x staining solution from the kit was then prepared and the 
pH was adjusted to 5.5. Slides were incubated with the staining solution overnight at 37oC. A 
small piece of parafilm was applied to each slide to ensure that the staining solution did not 
evaporate off. The following day excess staining solution was removed from the slides and 
the slides were counter stained with nuclear fast red for 5 minutes. Slides were then washed in 
dH20 for 5 minutes. Slides were mounted using DPX mounting medium.  
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2.7.2. Immunohistochemistry on paraffin sections: 
 
For all immunohistochemistry on paraffin sections, except for β-catenin, antigen retrieval was 
performed with citrate buffer either in the microwave or in the water bath (protocols below)  
 
Microwave antigen retrieval: 
Solution A (0.1M): 
10.5g of Citric Acid (molecular weight 192.12g: 10.5g/192.12g/mole = 0.055 moles)  
500 mls dH20 (M = 0.055 moles/0.500 L = 0.110M = 0.1M) 
Solution B (0.5M):  
29.4g Sodium Citrate (molecular weight = 58.44g: 29.4g/58.44g/mole = 0.503 moles) 
1 litre dH20 (M = 0.503 moles/1.000 L = 0.503M= 0.5M) 
 
To make a 1.5L solution: 27mls of solution A ([27mlx0.1M]/1500ml = 1.8mM) was mixed 
with 123mls of solution B ([123x0.1M]/1500ml = 8.2mM) and made up to 1.5L with dH20 
and adjusted to pH 6.0. The 1.5 L solution was placed in a pressure cooker and microwaved 
for 20 minutes or until the solution was boiling.  Slides were added and microwaved until the 
cooker was pressurised and then boiled for another 3-4 minutes. 
The pressure cooker was then removed and placed into a sink filled with cold water. Slides 
were removed and allowed to cool in solution for 20 minutes. 
 
Water Bath antigen retrieval: 
 
Citrate Buffer (Labvision) was diluted 1/10 in distilled water and 50ml of diluted citrate 
buffer solution was placed into a glass coplin jar. The coplin jar was immersed into a water 
bath and pre-heated to 99.9oC. Slides were immersed into a preheated solution and boiled for 
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20 minutes. The coplin jar was removed from the water bath and allowed to cool for 30 
minutes at room temperature in the solution. 
 
2.7.3. Immunohistochemistry for p21:  
 
The staining was done on paraffin embedded, ‘quick fixed’ samples.  This entailed the 
specimens being placed in a formalin fixative for less than 24 hours. 3um sections of tissue 
were cut onto Poly-L-lysine slides (Sigma).  Sections were dewaxed by placing into xylene 
for 20 minutes.  They were rehydrated through graded ethanol solutions (absolute alcohol, 
70% ethanol) and then into water. Antigen retrieval was performed as per the microwave 
method. Slides were washed 3x5 minutes in PBS. They were then blocked for 30 minutes 
with 5% goat serum in PBS.  Again they were washed 3x5 minutes with PBS. Slides were 
then incubated with Santa Cruz anti-p21 (M-19) (rabbit polyclonal) diluted 1/500 in 5% goat 
serum /PBS for 1 hour at room temperature. After this slides were washed again 3x5 minutes 
with PBS.  Slides were then incubated for 30 minutes with biotinylated secondary antibody 
from rabbit ABC kit (Vector Laboratories).  Slides were washed 3x5 minutes with PBS. 
Slides were then incubated with ABC solution for 30 minutes; 2 drops of solution A + 2 drops 
of solution B in 5 ml 5% goat serum/PBS. (made up 30 minutes earlier). DAB reagents were 
then mixed in the ratio 1ml substrate buffer to 1 drops chromogen. This was applied to slides 
and incubated for 5-10mins. Slides were wash 3x5 minutes with PBS. Slides were then 
transferred to dH2O.  
Slides were then counterstained in Haematoxylin for approximately 60 seconds before 
washing in running tap water for 5 minutes. Slides were dehydrated by washing in increasing 
concentrations of alcohols (1x5 minute wash in 70% alcohol, 2x5 minute washes in 100% 
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alcohol) before being placed in xylene for 2x10 minute washes. Slides were then mounted 
using DPX mounting medium.  
 
2.7.4. Immunohistochemistry for p16: 
 
Immunohistochemistry was performed as in 2.7.3. Exceptions: Slides were incubated with 
primary antibody to p16 (Santa Cruz M-156) 1/25 in 5% goat serum PBS for 1 hour at room 
temperature. Slides were then incubated for 30 minutes with biotinylated secondary antibody 
from rabbit ABC kit (Vector Laboratories).  
 
2.7.5. Immunohistochemistry for p19: 
 
Immunohistochemistry was performed as in 2.7.3. Exceptions: Antigen retrieval was 
performed as per the water bath method. Slides were incubated with primary antibody 
p19/ARF 1/300 (Upstate) in 5% goat serum PBS overnight at 40C. Slides were then incubated 
for 30 minutes with biotinylated secondary antibody from rabbit ABC kit (Vector 
Laboratories).  
 
2.7.6: β-Catenin Immunohistochemistry: 
 
Slides were cut and rehydrated as in 2.7.3. Slides were blocked for 30-45 minutes in the 
following block; 1 litre stock = 4.16g citric acid, 10.76g Na2HPO4 (DiSodium Hydrogen 
Phosphate 2 hydrate), 1g NaAz (Sodium Azide); add fresh H2O2 to 1.5%. For antigen 
retrieval, slides were boiled in a water bath for 50 minutes in Tris EDTA; 1 litre stock = 242g 
Tris, 18.6g EDTA. (10mM Tris Base, 1mM EDTA Solution).  For working solution, 30ml 
stock was diluted in 1500ml dH2O, adjusted to pH to 8.0 with HCl. Slides were allowed to 
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cool for 1 hour. Slides were then blocked for 30 minutes in 1% BSA in PBS. Slides were then 
incubated with β-catenin antibody (mouse monoclonal; C19220, Transduction Laboratories) 
1/50 in 1%BSA/PBS for 2 hours at room temperature. Then slides were washed 3x in PBS. 
Incubate slides with HRP-labelled polymer from Mouse Envision+ system (Dako systems) for 
1 hour at room temperature. Washed slides 3x in PBS. Slides were then developed with DAB, 
rehydrated and mounted as 2.6.3. 
 
2.7.7. BrdU Immunohistochemistry:  
 
Slides were cut and rehydrated as in 2.7.3. Antigen retrieval was performed as per the water 
bath method for 20 minutes. Slides were allowed to cool for 30 minutes at room temperature 
in solution. Slides were then rinsed in dH20. For prevention of endogenous staining, slides 
were blocked for 15 minutes in 1.5% H202 solution in dH20. Slides were then blocked for 30 
minutes in 1%BSA in PBS. Slides were then incubated with a 1/500 dilution of mouse anti-
BrdU (BD:cat N 347 580) diluted in PBS/1%BSA overnight at 40C. Slides were then washed 
3x in PBS and incubated with secondary polymer HRP-conjugated Envision+ (Mouse 
Envision+ system Dako Systems) for 1 hour at room temperature. Slides were then washed 3x 
5 minutes in PBS. Slides were then developed with DAB, rehydrated and mounted as in 2.6.3. 
 
2.7.8. p53 Immunohistochemistry:  
 
Slides were cut and rehydrated as in 2.7.3. For epitope retrieval slides were steamed for 40-45 
minutes in 10mM sodium citrate (pH 6.0), and cooled slowly at room temperature for 30 
minutes. Slides were then incubated in methanol/ H2O2 (180 mL meth. /20 mL 30% H2O2) 
for 20 minutes at room temp. They were then rinsed profusely with H2O. Slides were then 
blocked for 30 minutes at room temperature in normal serum from VECTASTAIN kit (4 
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drops serum/10 mL 1X PBS-0.1% Tween-20). Slides were then incubated with primary 
antibody diluted in blocking solution for 1-2 hours at room temperature (anti-p53 (CM5 from 
Vector laboratories) at 1:200 dilution), followed by 3x in PBS washes, and then incubated 
with secondary antibody from Vectastain Universal kit (1 drop/10 mL blocking solution) at 
room temperature for 30 minutes. 
Slides were washed 3x in PBS and then incubated slides with ABC solution for 30 minutes (2 
drops of solution A + 2 drops of solution B in 5 ml 5% goat serum/ PBS). Slides were then 
developed with DAB, rehydrated and mounted as in 2.6.3. 
 
2.7.9. MCM2 Immunohistochemistry: 
 
Slides were cut and rehydrated as in 2.7.3. Antigen retrieval was performed as per the 
microwave method. Slides were then blocked in 10% H2O2 made with dH2O for 10 minutes 
at room temperature. Slides were then washed with PBS 3x5 minutes, before being blocked in 
5% goat serum PBS for 30 minutes. Incubated slides with MCM2 (Cell signalling # 4007) 
rabbit polyclonal antibody at 1/200 with 5% goat serum PBS. Incubated overnight at 4oC. 
Washed slides with PBS 3x 5 minutes. Slides were then incubated with secondary polymer 
HRP-conjugated Envision+ (Rabbit Envision+ system Dako Systems) for 1 hour at room 
temperature. Slides were then washed 3x 5 minutes in PBS. Slides were then developed with 
DAB, rehydrated and mounted as in 2.6.3. 
 
2.7.10. Ki67 Immunohistochemistry: 
 
IHC was performed as per MCM2 IHC. Incubate with primary antibody: (Thermo; RM-9106) 
1/250 in 5% goat serum PBS for 1 hour at room temperature. Wash slides with PBS 3x5 
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minutes. Slides were then incubated with secondary polymer HRP-conjugated Envision+ 
(Rabbit Envision+ system Dako Systems) for 1 hour at room temperature. Slides were then 
washed 3x5 minutes in PBS. Slides were then developed with DAB, rehydrated and mounted 
as in 2.6.3. 
 
2.7.11. PTEN Immunohistochemistry 
 
Slide were cut and rehydrated as per 2.7.3. Antigen retrieval was performed as per the water 
bath method. Slides were then blocked in 3% H2O2 made with dH2O for 20 minutes at room 
temperature. Slides were then washed 2x5 minutes in dH2O, then 1x 5min TBS/T. Slides were 
then blocked for 45mins in 5% Goat Serum diluted in TBS/T at room temperature, followed 
by incubation in PTEN (Cell signalling # 9559) rabbit monoclonal antibody at 1/100 with  5% 
goat serum TBS/T overnight at 4oC. Washed slides with TBS/T 3x5 minutes, and incubated 
with secondary biotinylated goat anti-rabbit secondary Ab (DAKO) diluted 1/200 in 5% Goat 
Serum in TBS/T for 30mins at room temperature. Unbound secondary antibodies were 
washed off by 3x5 minutes TBS/T and signal reported with ABC solution for 30 minutes. 
Slides were washed slides 3x in PBS. Slides were then developed with DAB, rehydrated and 
mounted as in 2.6.3. 
 
2.7.12. p-AKT (Ser473) Immunohistochemistry 
 
Immunohistochemistry as per 2.7.10 except slides were then incubated with p-AKT (Ser473) 
(Cell signalling # 3787) rabbit monoclonal antibody at 1/100 with 5% goat serum TBS/T. 
Incubated overnight at 4oC.  
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2.7.13. p-mTOR (Ser2448) Immunohistochemistry 
 
Immunohistochemistry as per 2.7.10 except slides were then incubated with p-mTOR 
(Ser2448) (Cell signalling # 2976) rabbit polyclonal antibody at 1/100 with 5% goat serum 
TBS/T. Incubated overnight at 4oC.  
 
2.7.14. pERK1/2 Immunohistochemistry 
 
Immunohistochemistry as per 2.7.10 except slides were then incubated with p-ERK1/2 (Cell 
signalling # 9001) rabbit polyclonal antibody at 1/100 with 5% goat serum TBS/T. Incubated 
overnight at 4oC.  
 
2.7.15. pMEK1/2 Immunohistochemistry 
 
Immunohistochemistry as per 2.7.10 except slides were then incubated with p-MEK1/2 (Cell 
signalling # 2338) rabbit polyclonal antibody at 1/125 with 5% goat serum TBS/T. Incubated 
overnight at 4oC.  
 
2.7.16. p-S6 Kinase Immunohistochemistry 
 
Immunohistochemistry as per 2.7.10 except slides were then incubated with p-S6 Kinase 
(Thr421/Ser424) (Cell signalling # 9204) rabbit polyclonal antibody at 1/100 with 5% goat 
serum TBS/T. Incubated overnight at 4oC.  
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2.7.17. Active-Rac1 Immunohistochemistry 
 
Immunohistochemistry as per 2.7.10 except slides were then incubated with Active-Rac1 
(NewEast Biosciences # 26903) rabbit polyclonal antibody at 1/400 with 5% goat serum 
TBS/T. Incubated overnight at 4oC.  
 
2.7.18. GFP Immunohistochemistry 
 
Slide were cut and rehydrated as per 2.7.3. Antigen retrieval was performed as per the 
microwave method. Slides were then blocked in 3% H2O2 made with dH2O for 15 minutes at 
room temperature. Slides were then washed 3x 5min TBS/T. Slides were then blocked for 1 
hour in 5% Goat Serum diluted in TBS/T at room temperature. Slides were then incubated 
with GFP (AbCam #abcam6556) rabbit polyclonal antibody at 1/1000 with  5% goat serum 
TBS/T overnight at 37oC humidified. Slides were then washed with TBS/T 3x5 minutes, 
before being incubated with secondary antibody from Vectastain Universal kit (1 drop/10 mL 
blocking solution) at room temperature for 30 minutes. 
Slides were washed 3x in PBS. Incubated slides with ABC solution for 30 minutes; 2 drops of 
solution A + 2 drops of solution B in 5 ml 5% goat serum/ PBS. Washed slides 3x in PBS. 
Slides were then developed with DAB, rehydrated and mounted as in 2.6.3. 
 
2.7.19. Sprouty2 Immunohistochemistry 
 
Immunohistochemistry as per 2.7.15 except slides were then incubated with Sprouty2 
(AbCam # ab60719) mouse monoclonal antibody at 1/300 with 1%BSA/PBS overnight at 
4oC.  
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2.7.20. FGFR3 Immunohistochemistry 
 
Slide were cut and rehydrated as per 2.7.3. No antigen retrieval was performed. Slides were 
then blocked in 3% H2O2 made with dH2O for 20 minutes at room temperature. Slides were 
then washed 2x in 5min dH2O, then 1x 5min TBS/T. Slides were then blocked for 45mins in 
5% Goat Serum diluted in TBS/T at room temperature. Slides were then incubated with 
FGFR3 (Santa Cruz c-15) rabbit polyclonal antibody at 1/20 with  5% goat serum TBS/T 
overnight at 4oC.  Slides were then washed with TBS/T 3x5 minutes before being incubated 
with secondary biotinylated goat anti-rabbit secondary Ab (DAKO) diluted 1/200 in 5% Goat 
Serum in TBS/T for 30mins at room temperature. Washed 3x 5mins TBS/T.  Slides incubated 
with ABC solution for 30 minutes; 2 drops of solution A + 2 drops of solution B in 5 ml 5% 
goat serum/ PBS. Slides were then washed 3x in PBS. Slides were then developed with DAB, 
rehydrated and mounted as in 2.7.3. 
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2.8. Imaging 
 
2.8.1 Microscopy 
 
Light microscopy was carried out using the Olympus BX51.  All images were taken at 20x 
magnification, unless otherwise stated in the figure legends.  
For GFP in vivo imaging we used the Olympus OV100 system.  Mice were anesthetised by 
inhalation anaesthetic, using a mixture of O2 and isoflurane.  Imaging was also performed on 
mice post-mortem with both skin intact and removed. 
 
2.8.2. Ultrasound Scanning  
 
This was performed on live mice using Visualsonic’s Vevo 770 (Visulasonics Inc, Toronto, 
Canada). For all abdominal imaging mice were anaesthetised using 
hypnorm(fentanyl)/hypnovel(midazolam) 10ml/kg i.p.  To improve resolution an ascites 
protocol using an i.p. injection of 5ml of PBS was utilised.  
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2.9. Human Tissue Microarray (TMA) 
 
This was purchased from Folio biosciences (OH, USA) and consists of 60 cancer and 20 
benign bladder cancer cases with data on patient sex, age and tumour grade. Slides were 
scanned using the Aperio slide scanner (Pathology department, Western Infirmary). 
Protein expression levels were scored by two independent observers (Imran Ahmad and 
Lukram Babloo Singh, Research technician, The Beatson Insitute for Cancer Research), 
blinded to clinical parameters, using a weighted histoscore method, also known as the H-
score, at magnification ×40. Each cellular location (membranes, cytoplasm, and nuclei) was 
scored separately. The weighted histoscore method assesses the staining intensity and the 
percentage of cells stained with that intensity for the full slide. It is calculated by (1 × % cells 
staining weakly positive) + (2 × % cells staining moderately positive) + (3 × % cells staining 
strongly positive). This provides a semiquantitative classification of staining intensity, with 
the maximum score being 300 (if 100% of cells stain strongly positive) and minimum score 
being 0 (if 100% or cells are negative). The weighted histoscore method is a well-established 
method for scoring tissue that has heterogeneous staining.  Inter-observer agreement between 
the scorers was excellent with interclass correlation scores >0.80. 
I classified upregulation as a score ≥100 and downregulation as <100 (Kirkegaard et al., 
2006).  Correlation coefficient was calculated using SPSS v.15).  Multiple testing was taken 
into account (Bonferroni principle). 
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Chapter 3: β-Catenin activation synergises with PTEN loss to cause bladder 
cancer formation 
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3.1. Introduction 
 
A number of genetic and epigenetic alterations involved in bladder tumourigenesis have been 
identified, including activating mutations in FGFR3, and RAS family genes, amplification of 
ERBB2, and loss of the TP53, RB1 and PTEN tumour suppressors (Cordon-Cardo, 2008, Diaz 
et al., 2008, Luis et al., 2007, Schulz, 2006). However the role of the Wnt pathway in UCC 
has yet to be resolved. 
The Wnt/ β-catenin signalling pathway plays a crucial role in embryogenesis, cell 
differentiation and tumourigenesis. Wnts are secreted glycoproteins that act as ligands to 
stimulate receptor-mediated signal transduction pathways in both vertebrates and 
invertebrates (Moon et al., 2004).  In the absence of a Wnt signal, cytoplasmic β-catenin is 
phosphorylated and degraded in a complex of proteins. The complex which causes the 
phosphorylation of β-catenin and thus targets it for degradation is a multi-protein scaffolding 
complex, consisting of adenomatous polyposis coli (APC), glycogen synthase kinase 3β 
(GSK-3β), CK1 (casein kinase 1) and axin.  Following Wnt pathway activation (through the 
binding of a Wnt ligand to the frizzled transmembrane receptor), GSK3 is inactivated and β-
catenin is no longer phosphorylated and targeted for degradation.  As a result β-catenin 
accumulates in the cytoplasm and enters the nucleus, where it binds to TCF/LEF family 
members and transcriptionally regulates Wnt target genes which include cyclin D1 and c-myc 
(canonical Wnt signalling pathway) (Bienz and Clevers, 2000, He et al., 1998, Tetsu and 
McCormick, 1999, Polakis, 2000a). 
Mutations of the tumour suppressor PTEN have been described in many tumours (Salmena et 
al., 2008), including deletion of the locus in bladder cancers (Aveyard et al., 1999, Teng et al., 
1997, Tsuruta et al., 2006).  These deletions are absent/rare in superficial tumours, but occur 
frequently in invasive bladder cancers.  Previously published models of inactivation of PTEN 
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in the murine urothelium have shown widely conflicting phenotypes from benign epithelium 
to widespread hyperplasia whilst some demonstrate UCC after a long latency and with an 
incomplete penetrance (Puzio-Kuter et al., 2009, Tsuruta et al., 2006, Yoo et al., 2006, Qian et 
al., 2009).  This may be in part related to the different promoters, PTEN alleles and 
backgrounds of the mice used.  Recently it has been demonstrated that combined deletion of 
Pten and Trp53 in the murine urothelium results in aggressive UCC, which is dependent on 
mTOR signalling (Puzio-Kuter et al., 2009).  
In this study, I tested whether activation of Wnt signalling pathway may cooperate with loss 
of PTEN function to drive UCC in vivo. 
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3.2. Results 
 
3.2.1 β-catenin overexpression leads to benign hyperproliferation of the urothelium 
 
In order to drive deregulated Wnt signalling, I used mice that carry a dominant allele of the β-
catenin gene in which exon3 is flanked by loxP sequences (Harada et al., 1999). On addition 
of Cre recombinase, exon3 is deleted. As this exon contains the residues that are 
phosphorylated by GSK3β, leading to β-catenin degradation, β-catenin will therefore 
accumulate to drive Wnt signalling (Moon et al., 2004). To achieve urothelial specific 
expression of activated β-catenin, these mice were interbred with mice carrying an uroplakin 
II (UroII) CRE transgene (He et al., 2009, Mo et al., 2005). UroII is a protein localised at the 
apical surface of the urothelium and is important for its permeability barrier function (Zhang 
et al., 1999).  It is expressed throughout the urothelial layers in mice (Mo et al., 2005). The 
UroII promoter has been reported to successfully drive the expression of proteins including 
SV40 large T antigen and H-Ras (Zhang et al., 2001, Mo et al., 2007).  Previous studies have 
shown that the UroIICRE+ mice exhibit bladder specific recombination (Zhang et al., 1999). 
To confirm this and to report levels of recombination, UroIICRE+ mice were intercrossed 
with mice carrying the Z/EGFP reporter transgene (Novak et al., 2000). In the Z/EGFP 
reporter mouse, the Z/EGFP transgene results in the expression of β-galactosidase by most 
tissues via a β-geo insert, which is flanked by lox-P sites.  The presence of Cre recombinase 
results in the excision of the β-geo, activating the constitutive expression of GFP.  Both 
immunohistochemistry and OV100 imaging for GFP shows the expression of eGFP in the 
urothelial lining of the bladder and ureters (Figure 3.1) (Novak et al., 2000). 
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Figure 3.1: GFP Expression of UroIICRE+ Z/EGFP mice 
IHC for Green Fluorescent Protein (GFP) in wildtype (A) and 12-month old UroIICre+ 
Z/EGFP bladder (B).  Black bar measures 200µm (20x magnification). GFP visualised by 
OV100 shows evidence of Cre mediated recombination in the urothelium of 12-month old 
UroIICre+ Z/EGFP bladder (C). Imaging was performed ex-vivo after urine had been drained. 
Magnification at 14x.   
(At least 3 samples from each cohort stained and representative images are shown above). 
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Firstly, I used mice carrying one or two copies of the β-catenin exon3 allele to test whether 
the amplitude of the Wnt deregulation was important, as levels of deregulated Wnt signalling 
have been shown to be key in other organs such as the mammary gland (Howe and Brown, 
2004). To investigate the phenotype of β-catenin activation within the bladder I aged 
UroIICRE+ β-catenin+/+, UroIICRE+ β-cateninexon3/+ and UroIICRE+ β-cateninexon3/exon3 mice 
to 3 months of age. In mice carrying one or two copies of the β-catenin exon3 allele there was 
a clear phenotype in the bladder epithelium, with all mice developing areas of urothelial 
hyperplasia (Figure 3.2 A,C,E).  To confirm that this was due to the activation of β-catenin, I 
performed IHC for β-catenin and saw a marked upregulated of nuclear β-catenin compared to 
wildtype (Figure 3.2 B,D,F) as well as Wnt target gene c-Myc (Figure 3.3 A,D). To confirm 
the lesions were hyperproliferative I then stained for the proliferation markers Ki67 and 
BrdU, both of which I found to be upregulated (Figure 3.3 B,C,E,F). No differences in 
proliferation as assessed by BrdU positivity were observed in mice carrying either one or two 
copies of the β-catenin exon3 allele (data not shown).   
Given that mice formed hyperproliferative lesions I wished to test whether these mice 
developed UCC as they aged. Therefore UroIICRE+ β-catenin+/+, UroIICRE+ β-cateninexon3/+ 
and UroIICRE+ β-cateninexon3/exon3 mice were aged to 18 months old. Remarkably, no mice 
developed UCC within this time course and when bladders from these 18-month-old mice 
were examined they appeared equivalent to those at 3 months with a number of 
hyperproliferative lesions that had not progressed to cancer.  There was however a small yet 
significant increase in the numbers of lesions in bladders for each group of aged mice 
(p<0.001) (Figure 3.4). Interestingly given the paucity of lesions in the mutant bladders this 
suggests that secondary mutations are required in the recombined cells to allow these lesions 
to form, whilst the majority of singly β-catenin mutant cells that do not possess these 
additional mutations are being selected against. 
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The lack of invasive progression among these lesions highlights that β-catenin activation is 
not sufficient to drive UCC formation and potentially explains why subjects that carry 
germline mutations of APC do not develop UCC.  Similarly the lesions are composed of 
numerous proliferating cells, but never progress to tumours/overrun the urothelium.  This 
suggests that either there is a concordant high rate of apoptosis or the somehow these cells 
despite exhibiting markers of proliferation are not actually dividing (suggestive by 
upregulation of markers of senescence (Figure 3.5). 
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Figure 3.2: UroIICRE+ β-cateninexon3/exon3 urothelium demonstrates upregulation of 
nuclear β-catenin 
Histology from 12-month-old Wildtype and UroIICRE+ β-cateninexon3/exon3 mice. H&E reveals 
development of hyperplastic lesions in the mutant urothelium (black/red arrows) (A&C), of 
which a close up (red arrows) is seen in (E). Immunohistochemistry shows strong 
upregulation of nuclear β-catenin (B,D,F) compared to wildtype. Red bar measures 1000 µm 
(4x magnification), black bar measures 200µm (20x magnification).  Red box outline in (A) 
and (B) highlights the picture for (C) and (D). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 3.3: UroIICRE+ β-cateninexon3/exon3 urothelium demonstrates upregulation of Wnt 
target genes and proliferative markers 
IHC from 12-month-old Wildtype and UroIICRE+ β-cateninexon3/exon3 urothelium demonstrates 
strong upregulation Wnt target gene c-Myc (A&D), as well as upregulation of markers of 
proliferation; BrdU (B&E) and Ki-67 (C&F) in the mutant urothelia. Black bar measures 
200µm (20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 3.4: Box plot of lesion numbers in the wildtype, UroIICRE+ β-cateninexon3/+ and 
UroIICRE+ β-cateninexon3/exon3 
Box plot of lesion numbers in the wildtype, UroIICRE+ β-cateninexon3/+ and UroIICRE+ β-
cateninexon3/exon3 cohorts at 3, 12 and 18 months of age (n=3).  I showed that at 3, 12 and 18 
months the number of lesions in the UroIICRE+ β-cateninexon3/+ (e3/+) and UroIICRE+ β-
cateninexon3/exon3 (e3/e3) are significantly higher than the corresponding wildtype (WT) time 
point (*, p<0.001, Mann Whitney Test).  Similarly lesions at both 12 and 18 months in the 
UroIICRE+ β-cateninexon3/+ and UroIICRE+ β-cateninexon3/exon3 cohorts are significantly higher 
than the corresponding cohort at 3 months (#, p<0.001, Mann Whitney Test).  Thick bar 
represents median, and the box represents the inter-quartile range. 
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3.2.2. The PTEN tumour suppressor pathway is activated in the bladder lesions  
 
I next investigated the pathways that were constraining tumour progression within the areas of 
urothelial hyperplasia. UCC can be broadly separated into two molecular pathways (Luis et 
al., 2007, Wu, 2005).  In one pathway where patients have either FGFR3 or HRAS mutations, 
they develop superficial papillary disease, which often carries a good prognosis.  The other 
tumour subtype has a more aggressive phenotype, leading to muscle invasion and ultimately 
metastatic disease.  These tumours have often lost p53 and/or have an activation of the PI3-
kinase signalling pathway. Indeed, a recent study has shown that low PTEN levels correlate 
with a poor prognosis in human bladder cancer (Puzio-Kuter et al., 2009). This has recently 
been modelled in the mouse using adenoviral Cre infections into the bladder. Mice either 
singly mutant for Pten or Trp53 did not develop tumours, however double knockout mice 
developed metastatic urothelial cancer. Thus I next investigated the expression of candidate 
molecules from the p53 and PTEN tumour suppressor pathways within lesions from the 
UroIICRE+ β-cateninexon3/exon3 mice. Within the lesions, there were very high levels of the 
PTEN tumour suppressor protein expression (Figure 3.5 A&B) with associated minimal 
pAKT, p-mTOR and pS6 Kinase staining (Figure 3.5 D,F,H) suggesting that the PTEN 
tumour suppressor was potentially blocking tumour progression. In contrast to a large 
increase in PTEN, there was only a modest increase in the levels of nuclear p53 although one 
of its targets p21 was highly upregulated within the lesions of the mice (Figure 3.5 J&L).  
There was strong upregulation of p19ARF (Figure 3.6 N), another p53 related tumour 
suppressor.  Similarly I noticed upregulation of senescence-associated β-galactosidase 
(Saβgal) (Figure 3.5 P). 
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Figure 3.5: UroIICRE+ β-cateninexon3/exon3 urothelium demonstrates upregulation of 
PTEN, p53, p21 and p19ARF 
IHC from 12 month old Wildtype and UroIICRE+ β-cateninexon3/exon3 urothelium demonstrates 
strong upregulation PTEN (A&B), with minimal pAkt(Ser473) (C&D) and p-mTOR (E&F) 
signal. I also noticed significant upregulation of p-S6 Kinase, p21, p19ARF, p53 and Saβgal 
(G-P). Red bar measures 1000 µm (4x magnification), black bar measures 200µm (20x 
magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
120 
 
3.2.3. PTEN upregulation acts to block β-catenin driven urothelial proliferation 
 
As the uroplakin II cre recombinase is expressed throughout development of the urothelium, 
it is difficult to assess whether the upregulation of PTEN is a direct consequence of β-catenin 
accumulation. Therefore I next investigated the consequence of inducibly activating Wnt 
signaling in the adult urothelium. To do this mice carrying the cytochrome p450 inducible 
AhCreERT transgene were used. Following administration of both β-napthoflavone and 
tamoxifen, this yields cre-mediated recombination within the urothelium of the bladder (as 
well as the intestine) (Marsh et al., 2008). Figure 3.6 demonstrate recombination in the 
bladder as evidenced by GFP signalling identified by OV100 imaging (ex-vivo) and IHC for 
GFP in AhCreERT Z/EGFP reporter mice 7 days following induction. To investigate the 
impact of acutely activating Wnt signalling in the adult bladder I intercrossed AhCreERT mice 
to mice carrying the inducible knockout Apc580S allele (from here on known as Apcfl) in which 
loxp sites are inserted into the introns around exon 14 (Shibata et al., 1997). Remarkably, 
examination of the bladders from AhCreERT Apcfl/fl mice seven days following induction 
revealed development of urothelial lesions which phenocopied those from our UroIICRE+ β-
cateninexon3/exon3 mice (Figure 3.7 A). Indeed there were more lesions in the AhCreERT Apcfl/fl 
urothelia suggesting a greater recombination frequency than the UroIICRE+.  Consistent with 
the activation of Wnt signalling, lesions demonstrated a high level of nuclear β-catenin and 
again an upregulation in BrdU incorporation compared to the surrounding urothelium (Figure 
3.7 B&C). Importantly, once again very high levels of PTEN were seen within these lesions 
(Figure 3.7 D) with minimal upregulation of pAKT (Figure 3.7 E). To confirm this was due to 
increased levels of Wnt signalling, I also activated Wnt signalling by deleting both copies of 
GSK3α and GSK3β.  Bladders from induced AhCreERT GSK3αβfl/fl mice displayed similar 
lesions to the AhCreERT Apcfl/fl mice, with the accumulation of nuclear β-catenin, BrdU and 
PTEN (Figure 3.8 A-D) (MacAulay et al., 2007, Patel et al., 2008, Kemp et al., 2004). Using 
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this induction regime, mice developed hyperplastic intestinal epithelium, which precluded 
long term tumour experiments, however in mice aged up to 4 months bladder lesions still 
remained small and did not progress to cancer, suggesting PTEN was once again blocking 
tumourigenesis. 
 
 
Figure 3.6: GFP expression in AhCreERT Z/EGFP mice 7 days post induction 
Bladders from AhCreERT Z/EGFP mice reveal recombination in the bladder as evidenced by 
GFP signalling, identified by IHC for GFP (B) compared to wildtype (A). OV100 imaging 
(ex-vivo) (C). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 3.7: Histology of AhCreERT Apc fl/fl 7 days post induction 
Bladders from AhCreERT Apcfl/fl mice reveal similar hyperproliferative lesions to our 
UroIICRE+ β-cateninexon3/exon3 (A), which demonstrate proliferation (C) as well as 
upregulation of nuclear β-catenin and PTEN staining with minimal pAKT expression (B,D,E). 
Black bar measures 200µm (20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 3.8: Histology of AhCreERT GSK3αβ fl/fl mice 7 days post induction 
AhCreERT GSK3αβ fl/fl mice reveal bladder lesions (A), which demonstrate proliferation as 
well as accumulation of nuclear β-catenin and PTEN (B-D). Black bar measures 200µm (20x 
magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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To test the role PTEN was having immediately following Apc loss in the urothelium I 
generated AhCreERT APC fl/fl PTEN fl/fl mice. Seven days following induction, the mice again 
developed urothelial lesions that were much larger than in AhCreERT Apcfl/fl Pten+/+ mice 
(Figure 3.9 A). These lesions showed an accumulation of nuclear β-catenin, high BrdU 
expression and consistent with PTEN deletion, a complete absence of PTEN staining in the 
lesions (Figure 3.9 B-D), and showed strong pAKT(Ser473) upregulation (Figure 3.9 E) To 
investigate whether the reason for the enlarged lesions was due to hyperproliferation, I 
examined the number of BrdU positive cells per lesion in both AhCreERT Apcfl/fl and 
AhCreERT Apcfl/fl Ptenfl/fl mice and demonstrated a statistically significantly increase in 
proliferation when PTEN is lost (p<0.05, Mann Whitney Test) (Figure 3.10).  Thus PTEN 
accumulation following β-catenin activation is acting to limit proliferation.  I was again 
unable to further analyse the AhCreERT Apcfl/fl Ptenfl/fl mice as these mice became ill rapidly 
after induction due to intestinal disease at day 8. 
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Figure 3.9: Histology of AhCreERT Apcfl/fl Ptenfl/fl 
Bladders from AhCreERT Apcfl/fl Ptenfl/fl mice reveal larger lesions (A) that show further 
proliferation (B), nuclear β-catenin (C), but this time the absence of PTEN staining in the 
lesions (D). These lesions demonstrate significant upregulation of pAKT (E). Black bar 
measures 200µm (20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 3.10: Box plot of average number of BrdU positive cells per lesion in both 
AhCreERT Apcfl/fl  and AhCreERT Apcfl/fl Ptenfl/fl mice. 
Urothelium assessed at 7 days after first induction (n=3) (p<0.001, Mann Whitney test). Total 
number of positive cells from lesions (n=3) counted from 3 mice (total lesions n=9), with 
median, inter-quartile range and range represented above. 
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3.2.4. PTEN loss cooperates with β-catenin activation to drive UCC formation  
 
To test whether this block of proliferation by PTEN was suppressing tumourigenesis I 
intercrossed UroIICRE+ β-cateninexon3/exon3 mice with mice carrying a conditional 
inactivatable Pten allele (where exon 5 is flanked by lox p sites) (Lesche et al., 2002). A 
recent study using adenoviral Cre delivery to the bladder has shown that deletion of Pten 
alone in the murine urothelium is not sufficient to promote bladder cancer formation (Puzio-
Kuter et al., 2009). I have confirmed this result here, as neither UroIICRE+ Ptenfl/+ nor 
UroIICRE+ Ptenfl/fl mice developed cancer when aged until 18 months (n=20).  Indeed, no 
phenotypic changes (dysplasia, hyperplasia or tumourigenesis) were observed in urothelium 
between UroIICRE+ Ptenfl/fl and wildtype mice (Figure 3.11 A-B). To confirm that Pten was 
deleted in these mice I stained for PTEN levels by IHC and found a downregulation of the 
PTEN protein in bladders from UroIICRE+ Ptenfl/fl  (Figure 3.11 C-D) and only a modest 
upregulation of pAKT(Ser473) staining  (Figure 3.11 E-F). These data are consistent with 
previous studies within the intestinal epithelium where Pten deletion was not sufficient to 
drive tumourigenesis and only modestly affected the levels of pAKT (Marsh et al., 2008).  
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Figure 3.11: Histology of UroIICRE+Ptenfl/fl mice 
Comparison of 12-month-old wildtype and UroIICRE+Ptenfl/fl urothelium.  The H&E 
demonstrates that the urothelium of UroIICRE+Ptenfl/fl (B) is comparable to wildtype (A) with 
no hyperplasia, dysplasia or tumour formation.  Lower levels of PTEN in the 
UroIICRE+Ptenfl/fl urothelium (D) when compared to wildtype (C) and slightly elevated levels 
of pAkt(Ser473) (E,F) were observed.  Black bar measures 200µm (20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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To study the simultaneous activation of β-catenin and PTEN loss, the following cohorts were 
generated: UroIICRE+ β-cateninexon3/+Ptenfl/+, UroIICRE+ β-cateninexon3/exon3Ptenfl/+, 
UroIICRE+ β-cateninexon3/+Ptenfl/fl, and UroIICRE+ β-cateninexon3/exon3Ptenfl/fl (n= 20, 16, 24, 21 
respectively).  A cohort of these mice was harvested at 3 months of age and the bladder 
phenotypes were analysed.  A second cohort of mice was allowed to age until clinical 
evidence of tumour development, or when animals were required to be sacrificed per project 
license guidelines.  At 3 months of age, hyperplastic lesions (scored from 3 H&E cross 
sections of each mouse, with 3 mice in each cohort) were observed at an increased frequency 
in doubly mutant mice compared with mice carrying only β-catenin mutation (Figure 3.12).   
 
 
 
 
 
 
 
 
 
 
 
 
 
130 
 
 
 
 
 
 
Figure 3:12 Tumour burden of UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl mice 
Box plot of number of lesions found in urothelium of each cohort at 3 and 12 months (n=3). 
Cohorts denoted by * demonstrate significantly elevated levels of lesions in comparison to 12 
month old UroIICRE+ β-cateninexon3/exon3 (p<0.05, Mann Whitney Test).  Abbreviations: e3/e3 
(UroIICRE+ β-cateninexon3/exon3), e3/+ fl/+ (UroIICRE+ β-cateninexon3/+ Ptenfl/+), e3/e3 fl/+ 
(UroIICRE+ β-cateninexon3/exon3 Ptenfl/+), e3/+ fl/fl (UroIICRE+ β-cateninexon3/+ Ptenfl/fl) and 
e3/e3 fl/fl (UroIICRE+ β-cateninexon3/exon3Ptenfl/fl). Thick bar represents median, and the box 
represents the inter-quartile range. 
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In contrast to the UroIICRE+ β-cateninexon3/+Ptenfl/+ and UroIICRE+ β-cateninexon3/exon3Ptenfl/+ 
mice, the UroIICRE+ β-cateninexon3/exon3Ptenfl/fl mice and UroIICRE+ β-cateninexon3/+Ptenfl/fl 
mice rapidly developed symptoms of bladder tumour; abdominal swelling, haematuria (blood 
in the urine) and hunching (Figure 3.13 & 3.14). Mice with loss of both copies of Pten 
succumbed to bladder tumours 100 days earlier than those with single copy loss.   
On necropsy, the presence of bladder tumour was confirmed, which showed histological 
progression to papillary carcinoma (Figure 3.15 A&B). I found no evidence of metastasis in 
any of the models studied (both at macroscopic and microscopic level, with multiple sections 
taken through the lung, liver, spleen, diaphragm, kidneys and local lymph nodes). Consistent 
with Pten deletion, the tumours that developed showed complete loss of PTEN protein and 
now displayed strong activation of pAKT(Ser473) (Figure 3.15 C&D). Tumours also showed 
a nuclear upregulation of β-catenin and Ki-67 (Figure 3.15 E&F).   
These data are consistent with tumour formation in the bladder being synergistically promoted 
by Wnt and PI3 kinase signalling. This scenario fits with our previous studies in the intestinal 
epithelium where Wnt activation or Pten loss alone, were not sufficient to induce high levels 
of pAKT and presumably PI3 kinase signalling (Marsh et al., 2008). However in our bladder 
model, combination of deregulated Wnt signalling and PTEN loss caused a dramatic increase 
in pAKT that presumably drives tumour formation.  Of the targets downstream of pAKT, I 
also saw a dramatic increase in p-mTOR2448 (Figure 3.15 G), suggesting that mTOR 
activation is a key component of tumourigenesis in this model.  A recent chemoprevention 
study by Puzio-Kuter has shown that mTOR inhibition using Rapamycin suppresses 
tumourigenesis in Trp53/Pten double knockout tumours (Puzio-Kuter et al., 2009). Consistent 
with our tumours being dependent on PI3-kinase signalling, there was no upregulation of 
pERK1/2 in the tumours (Figure 3.15 H).  There was minimal upregulation of p53 and p21 
132 
 
(Figure 3.15 J&K).  By 12 months of age, a small subset of the UroIICRE+ β-cateninexon3/exon3 
Ptenfl/+ mice and UroIICRE+ β-cateninexon3/+Ptenfl/+ mice had developed tumours. This was 
presumably due to the loss of the remaining Pten allele, as staining for PTEN was absent from 
the tumours (Figure 3.15 I). There has been much debate over the crosstalk between the Wnt 
and PI3 kinase pathways and it is often proposed that the inhibitory phosphorylation of GSK3 
by AKT/PKB may allow the activation of Wnt signalling. If this was the case one would 
argue that PTEN loss alone should be sufficient to activate Wnt signalling and numerous 
studies have shown that this is not the case (including our present study) (Salmena et al., 
2008).  Moreover two key studies suggest that the phosphorylation of GSK3 by AKT does not 
affect Wnt signalling. First ‘knock-in’ mice where the AKT phosphorylation sites on 
GSK3alpha (Ser21) and GSK3beta (Ser9) were converted to alanine did not elevate Wnt 
signalling (McManus et al., 2005). Second a recent study has shown that the Wnt pool of 
GSK3 is physically distinct from the AKT pool (Ng et al., 2009).  Our data here shows it is 
only in the complete genetic absence of both GSK3α and GSK3β that Wnt signalling is 
deregulated (Figure 3.8). 
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Figure 3:13 Survival of UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl mice 
Kaplan Meier curves of tumour free survival of respective double mutant cohorts. 
Abbreviations: e3/+ fl/+ (UroIICRE+ β-cateninexon3/+ Ptenfl/+), e3/e3 fl/+ (UroIICRE+ β-
cateninexon3/exon3 Ptenfl/+), e3/+ fl/fl (UroIICRE+ β-cateninexon3/+ Ptenfl/fl) and e3/e3 fl/fl 
(UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl).  Log rank test indicates significant difference between 
e3/+fl/+ / e3/e3 fl/+ and e3/+ fl/fl / e3/e3 fl/fl cohorts (p<0.001). 
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Figure 3:14 Photograph of UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl bladder tumour 
The whole bladder here has been replaced by tumour, creating the solid mass seen above. 
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Figure 3.15: Histology of a UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl mice 
Histology of a UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl mice reveals urothelial bladder tumour 
(A,B) with loss of PTEN (C) and upregulation of pAKT(Ser473) in these tumours (D).  There 
is also upregulation of nuclear β-catenin (E), Ki67 (F) and mTOR(Ser2448) (G).   I noticed no 
upregulation in pERK1/2 in these tumours (H).  By 12 months of age, a small subset of the 
UroIICRE+ β-cateninexon3/exon3 Ptenfl/+ mice and UroIICRE+ β-cateninexon3/+ Ptenfl/+ mice had 
developed tumours, presumably due to the loss of the remaining Pten allele (I). Tumours 
demonstrate minimal upregulation of p53 (J) and p21 (K).  There is significant upregulation 
of p-S6 Kinase (L). Red bar measures 1000 µm (4x magnification), black bar measures 
100µm (40x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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3.2.5. UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl UCCs are mTOR dependent 
 
Given mTOR is one of the key tumour promoting pathways downstream of PTEN loss, I next 
investigated whether tumours from UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl mice would remain 
dependent on mTOR even if they were fully established. Therefore I treated UroIICRE+ β-
cateninexon3/exon3 Ptenfl/fl mice at 6 months of age with Rapamycin (10mg/kg i.p. daily), a 
potent inhibitor of mTOR, or vehicle (n=3) when mice had a detectable tumour using 
Visualsonic’s Vevo 770 ultrasound. Remarkably I was able to demonstrate regression of 
tumour bulk between initiation and the end of treatment (Figure 3.16 A-D). All mice on 
treatment survived the 4-week experiment, however in the vehicle treated mice cohort, 2 mice 
had to be sacrificed early (7 and 11 days) because of tumour burden.  IHC for p-mTOR2448 
revealed significant upregulation of this pathway in UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl 
mice.  However when treated with 4 weeks of Rapamycin I noticed regression of the lesions 
and downregulation of the protein staining, as well as downstream targets p-S6 kinase and p-
4EBP1 (Figure 3.16 E&F and 3.17). I noticed a statistically significant reduction in the BrdU 
positive cells in the tumours from the Rapamycin treated mice compared to the vehicle 
controls (p<0.05, Mann Whitney Test) (Figure 3.18). 
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Figure 3.16: UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl mice treated with Rapamycin 
Analysis of UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl mice treated with 4 weeks of daily IP 
injections of Rapamycin (10mg/kg). Ultrasound imaging reveals shrinking of the tumour in 
the treated mice bladders between initiation (A) and end of treatment (B) regimes. I saw 
regression of tumour formation (C) from non-treated controls.  Boxplot shows that bladders of 
treated mice have less tumour bulk p<0.05, Mann Whitney Test) (D). IHC for p-mTOR 
reveals significant upregulation of this pathway in UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl mice 
(E).  However when treated with 4 weeks of Rapamycin I noticed regression of the lesions 
and downregulation of the protein staining (F). Black bar represents 100µm (all 
magnifications at 40x). 
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Figure 3.17: UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl mice treated with Rapamycin 
Additional IHC for p-mTOR reveals significant downregulation of this pathway in 
UroIICRE+ β-cateninexon3/exon3 Ptenfl/fl mice after treatment with Rapamycin (A,B).  Similarly I 
also demonstrate that p-4EBP1 and p-S6 Kinase, a known target of the mTOR pathway, is 
downregulated after treatment (C-F).  Black bar represents 100µm (40x objective). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 3.18: Proliferation of tumours in Rapamycin treated mice versus vehicle control 
Boxplot indicating reduction of BrdU positive cells per 20x field view of bladder tumours 
treated with Rapamycin versus those treated with vehicle control (p<0.05, Mann Whitney 
Test).  At least 3 areas scored from each slide (n=3).  Thick lines represents median, box 
represents inter-quartile range and whiskers the range. 
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3.2.6. Human UCC demonstrate correlation between Wnt activation and PTEN loss 
 
In human urothelial cancer, a number of studies have suggested Wnt signalling is important. 
Of particular note is the demonstration that nuclear β-catenin is associated with a poor 
prognosis, and methylation of the genes encoding inhibitors of Wnt signalling, the SRFPs, act 
as markers of a bad prognosis (Marsit et al., 2005, Urakami et al., 2006a, Urakami et al., 
2006b). Indeed the methylation of these genes has been suggested as a marker of invasive 
bladder carcinoma.   
A tissue microarray of human bladder UCC containing 80 cases, 60 UCC (transitional cell 
carcinomas [TCC]) and 20 benign controls (Folio biosciences, OH, USA), was studied. Using 
the histoscore technique to quantitate immunoreactivity, upregulation of β-catenin expression 
and loss of PTEN signal were found to be significantly associated (n=36/56, cc=0.314, 
p<0.01, SPSS v15). Upregulated expression of β-Catenin and pAKTSer473 were similarly 
associated (n=30/56, cc=0.471, p<0.001, SPSSv15) (Figure 3.19 and 3.20). Taken together, 
loss of PTEN and resulting upregulation of pAKT is essential for Wnt driven UCC to 
progress.  
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Figure 3.19: Human Bladder UCC TMA 
IHC of 3 human bladder transitional cell carcinoma cases (A-C, D-F and G-I) revealing 
upregulation of β-catenin (A&D), loss of corresponding PTEN signal (B&E) and upregulation 
of pAKTSer473 (C&F). Conversely a few samples showed upregulation of PTEN (H) with 
minimal β-catenin and pAKTSer473 signal (G&I). 
Each core size is 1.5mm 
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Figure 3.20: Correlation between β-catenin and PTEN/pAKT in Human Bladder UCC 
TMA 
Table demonstrating proportions of cores that show combinations of up- and downregulation 
of β-catenin and PTEN/pAKT (Upregulation is classified as ≥100 and downregulation as 
<100 using the histoscore technique) (A). Scatterplot demonstrating correlation between β-
catenin and pAKT (B).  
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3.3. Discussion 
 
Data presented in this chapter suggests that activation of Wnt signalling cooperates with other 
mutations such as loss of PTEN/activation of pAKT to drive bladder carcinogenesis. This 
may indicate that the significance of Wnt signalling in human bladder cancer has been 
underestimated, due to the relatively rare nature of APC and β-catenin mutations. 
Traditionally up to a quarter of bladder tumours are thought to exhibit nuclear β-catenin 
(Kastritis et al., 2009). Instead the Wnt signalling pathway may be involved by epigenetic 
inactivation or mutations in other components of the pathway (e.g. secreted frizzled related 
proteins). Patients with Wnt dependent tumours may be identified by IHC for proteins such as 
β-catenin or downstream proteins such as c-Myc.  Unfortunately the active epitope for β-
catenin rapidly degrades unless the samples are processed and embedded within 24 hours, 
which is not always practical for clinical samples.  Thus there is a need to identify more 
robust biomarkers for Wnt pathway activation that we can transfer to the clinic. 
Indeed our studies would suggest in those patients where tumours had high levels of β-catenin 
and p-AKT, the combination of mTOR and Wnt inhibition might be an attractive 
combination.  My TMA results are exciting, but still very preliminary, since they are carried 
out on a relatively small cohort of patients (n=80).  I am currently repeating these studies on 
larger powered cohorts. 
Recently, antibody-based therapies have also been developed that target molecules of the Wnt 
pathway (such as Wnts and Frizzleds) that are over-expressed in disease (Nagayama et al., 
2005, You et al., 2004).  These tumours may be responsive to antibodies that inhibit Wnt 
signalling through blocking ligand binding such as Frizzled8CRD-hFc (DeAlmeida et al., 
2007).  These are currently being developed and tested in preclinical tumour models. 
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X-ray structure analysis of components of the Wnt pathway (β-catenin, Axins, APC, TCFs, 
Dishevelled, BCL9 and their complexes) will allow future design and testing of novel 
compounds targeting this pathway, and a number of high-throughput screening programmes 
to discover such compounds are currently underway (Klaus and Birchmeier, 2008).  Future 
evaluation of combined inhibition of the mTOR and Wnt pathways is desirable.  This would 
indeed be the first steps towards “personalised” medicine, in which each tumour has its 
molecular signature analysed and subsequent treatment regimes are based on these finding.  
So it would not be unreasonable to suggest our subset of UCC patients with upregulation of 
the Wnt and PI3K pathways may receive a combination of Wnt and PI3K inhibitors for their 
tumours. 
Taken together, I showed original data supporting a causative role for β-catenin in the 
formation of UCC in vivo and provide definitive evidence that activating mutations in the Wnt 
pathway promote UCC when combined with loss of PTEN/activation of the PI3K pathway. 
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Chapter 4: Ras mutation cooperates with β-catenin activation to drive 
bladder tumorigenesis 
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4.1. Introduction 
 
In the previous experimental chapter, I explored the causative role of β-catenin in the 
formation of UCC in vivo, and showed that activating mutations in the Wnt pathway promote 
UCC when combined with loss of PTEN/activation of the PI3K pathway.  
H-Ras was the first human oncogene isolated in human UCC, being mutated most often at 
codon 12, 13 and 61 (Reddy et al., 1982). As well as becoming constitutively active, 
overexpression of the protein due to alternative splicing of the last intron can also occur. 
Despite the controversy regarding the reported mutation frequency rate recent studies indicate 
that HRAS mutation occurs in approximately in 30-40% of UCC (Kompier et al., 2010).  
Transgenic models have provided invaluable information regarding the molecular 
mechanisms behind HRAS activation (See section 1.6.1.1.). 
Conversely few studies have looked at K-Ras mutations in human bladder cancer, although 
those that have suggest a wide variation in frequency (4-29%) (Ayan et al., 2001, Uchida et 
al., 1995, Olderoy et al., 1998).  Interestingly a study by Vageli and colleagues demonstrated 
the K-Ras oncogene was overexpressed in 15 of the 26 (58%) samples (Vageli et al., 1996).  
Unfortunately, as with many of these studies there was no segregation of samples into non-
invasive and muscle invasive tumours.  
As I have outlined previously the human data regarding Wnt pathway activation is highly 
controversial.  It is now becoming clear that the pathway is activated in a proportion of UCCs, 
but whether these are segregated to the non-invasive, papillary pathway or the muscle 
invasive pathway is yet to be fully elucidated.    
I have previously shown that UroIICRE+ β-cateninexon3/exon3 mice develop hyperproliferative 
lesions that do not progress to invasive UCC despite aging. As demonstarted the HRAS mice 
(low-copy) develop tumours only after a very long latency (up to 26 months) with an 
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incomplete penetrance (63%), despite demonstrating significant hyperproliferation at an early 
stage (Zhang et al., 2001).  This is suggestive that additional mutations may be required to 
drive the non-invasive, papillary, UCC phenotype.  Despite K-Ras being implicated in human 
UCC, there are no murine models as yet published. 
Thus the aim of this part of my project was to test the effect of Ras overexpression or its 
mutation on the murine urothelium in vivo to promote carcinogenesis, and its interaction with 
a background of upregulated Wnt signalling. 
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4.2. Results 
 
4.2.1. Ras activation alone does not lead to UCC in the mouse  
 
To test whether oncogenic Ras mutation would lead to UCC, UroIICRE+ mice were 
intercrossed to mice carrying either oncogenic K-Ras G12D allele (Jackson et al., 2001) or 
constitutively active H-Ras oncogene (“low-copy”) (Zhang et al., 2001). I demonstrated that 
neither UroIICRE+K-RasG12D/+ nor H-RasQ61L mice developed cancer when aged to 12 months 
of age (n=20).  Indeed, no phenotypic abnormalities were observed in the urothelium of 
UroIICRE+K-RasG12D/+ mice (Figure 4.1 A&B). There was minimal proliferation as observed 
by Ki67 staining (Figure 4.1 D&E), with significant upregulation of pERK1/2 compared to 
wildtype (Figure 4.1 G&H). I noticed no upregulation of pAKT, p21, pMEK, Active-Rac1 or 
β-catenin (Figure 4.1 J-K, M-N, Q-P, S-T, and V-W). 
In comparison, as previously published, I noticed global hyperplasia of the 12 month old H-
RasQ61L urothelium compared to wildtype (Figure 4.2 C) (Zhang et al., 2001). These “low 
copy” mice have 2 copies of the oncogenic rabbit transgene.  Although Zhang et al 
demonstrated tumour latency from 10-26 months of age; no tumours were observed in our H-
RasQ61L mice cohort at sacrifice (12 months of age). These aged mice again demonstrated 
strong upregulation of pERK1/2 with upregulation of Ki67 and p21 (Figure 4.1 F, I, O), 
without evidence of any upregulation of pAKT signal (Figure 4.1 L).  There was minimal 
upregulation of pMEK and Active-Rac1, although there is some β-catenin staining, there is 
only the occasional sporadic cell that exhibited nuclear staining (Figure 4.1 R,U,X).  This may 
be due to partial Wnt pathway activation by upregulation of the MAPK pathway in the H-
RasQ61L mutant urothelium. 
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Figure 4.1: Histology from 12-month-old Wildtype, UroIICRE+K-RasG12D/+ and H-
RasQ61L mice 
Wildtype, UroIICRE+ K-RasG12D/+ (oncogenic point mutation, endogenous levels) and H-
RasQ61L (rabbit transgene, multiple copies) urothelia H&E (A-C), Ki67 (D-F), perk (G-I), 
pAKT (J-L), p21(M-O), β-catenin (P-R), pMEK (S-U) and Active-Rac1 (V-X). 
Black bar measures 200µm (20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Thus I next investigated the expression of candidate molecules from the FGFR3 and RAS 
oncogenic pathways within lesions from the UroIICRE+ β -cateninexon3/exon3 mice. Within the 
lesions I saw minimal levels of STAT3 signalling (Figure 4.2 C), though very high levels of 
pERK1/2 staining was present (Figure 4.2 D) suggesting a role of the Ras signalling pathway.  
 
 
 
 
 
Figure 4.2: Histology from 12 month old UroIICRE+ β-cateninexon3/exon3 mice.  
Within these urothelial lesions I see comparable (minimal) STAT3 staining to wildtype 
(A&C) with significant upregulation of pERK1/2 compared to wildtype (B&D) signal.  
Black bar measures 200µm (20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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4.2.2. Ras activation cooperates with β-catenin to drive UCC formation  
 
To test the cooperation of β-catenin and Ras activation I next generated the following cohorts: 
UroIICRE+ β-cateninexon3/exon3 K-RasG12D/+ and UroIICRE+ β-cateninexon3/exon3 H-RasQ61L (n= 
25 and 29 respectively).  Two cohorts were studied, with mice sacrificed at 3 months of age or 
aged mice until tumour development, and then bladder phenotypes were characterised.  In 
contrast to the singly mutant mice, the UroIICRE+ β-cateninexon3/exon3 K-RasG12D/+ (mean 
survival 185 days, median 200 days) and UroIICRE+ β-cateninexon3/exon3 H-RasQ61L (mean 
survival 231 days, median 236 days) mice rapidly developed symptoms of bladder 
tumourigenesis, namely abdominal swelling, haematuria (blood in the urine) and hunching 
(Figure 4.3). On necropsy, I observed bladder tumours with histological progression to non-
invasive papillary carcinomas (Figure 4.4 A&B). I found no evidence of metastasis in any of 
our models. Unfortunately a proportion of our UroIICRE+ β-cateninexon3/exon3 K-RasG12D/+ 
mice developed lung tumours.  These mice were excluded from this analysis and will be 
discussed in more detail in section 5.2.3. 
Tumours from both models showed a nuclear upregulation of β-catenin and Ki-67 (Figure 4.4 
C-F).  The numbers of proliferating cells within tumours (identified by Ki-67 and BrdU IHC) 
were much higher than in the UroIICRE+ β-cateninexon3/exon3 mice (Figure 4.5), possibly 
explaining why lesions do not progress in the single mutant. I observed significant 
upregulation of pERK1/2 (Figure 4.4 G-H), with minimal levels of pAKT (Figure 4.4 I&J), 
similar to what was observed in the single β-catenin and Ras mutant mice.  The PTEN signal 
is still intact in these tumours (Figure 4.4 K&L). In both sets of tumours I noticed 
upregulation of the tumour suppressor p21 (Figure 4.4 M&N).  This upregulation is 
particularly marked in the UroIICRE+ β-cateninexon3/exon3 K-RasG12D/+ mutants since the K-Ras 
single mutants have minimal p21 staining.  Interestingly when I quantified the p21 positive 
cells (per field view) between H-RasQ61L and the UroIICRE+ β-cateninexon3/exon3 H-RasQ61L 
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mice I noticed a significant drop in positivity in the tumours compared to the hyperplastic 
urothelium of the single mutant (Figure 4.6). 
These data are consistent with tumour formation in the bladder being synergistically promoted 
by Wnt and MAPK signalling.  
 
 
 
 
Figure 4.3: Kaplan Meier curves of tumour free survival of respective mutant cohorts 
Abbreviations: WT (wildtype), U K-Ras (UroIICRE+K-RasG12D/+), U H-Ras (H-RasQ61L), UB 
K-Ras (UroIICRE+ β-cateninexon3/exon3K-RasG12D/+), UB H-Ras (UroIICRE+ β-cateninexon3/exon3 
H-RasQ61L).  Log rank test reveals significant reduction in survival of UB K-Ras and UB-H-
Ras compared to WT/U K-RAS/U H-Ras (p<0.001). 
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Figure 4.4: Histology of UroIICRE+ β-cateninexon3/exon3K-RasG12D/+ and UroIICRE+ β-
cateninexon3/exon3 H-RasQ61L mice: 
Reveals urothelial bladder tumours (A&B). I stained for Ki67 (C&D), β-catenin (E&F), 
pERK1/2 (G&H), pMEK (O&P), pAKT (I&J) and PTEN (K&L). Black bar measures 200µm 
(20x magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 4.5: Boxplot comparing Ki67 positivity between UroIICRE+ β-cateninexon3/exon3, 
UroIICRE+ β-cateninexon3/exon3 H-RasQ61L and UroIICRE+ β-cateninexon3/exon3K-Ras mice 
Boxplot indicating increase of Ki67 positive cells between the 3 cohorts of mice (p<0.001, 
Mann Whitney Test).  At least 3 areas from each slide scored (3 mice per cohort). Thick line 
represents median, box represents inter-quartile range and whiskers represent range. 
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Figure 4.6: Boxplot comparing p21 positivity between H-RasQ61L and UroIICRE+ β-
cateninexon3/exon3 H-RasQ61L mice 
Boxplot indicating reduction of p21 positive cells between the 2 cohorts of mice (p<0.001, 
Mann Whitney Test). At least 3 areas from each slide scored (3 mice per cohort). Thick line 
represents median, box represents inter-quartile range and whiskers represent range. 
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4.2.3. p21 upregulation blocks β-catenin driven UCC 
 
As I have shown p21 levels are upregulated in the H-RasQ61L hyperplastic urothelium, but in 
the UroIICRE+ β-cateninexon3/exon3 H-RasQ61L tumours I noticed a significant drop in p21 
positivity.  This is a similar picture to the UroIICRE+ β-cateninexon3/exon3 urothelium, where I 
see significant upregulation of p21 in the lesions, but this disappears in the UroIICRE+ β-
cateninexon3/exon3Ptenfl/fl tumours.  In both cases there appears to be a bladder-specific 
upregulation of p21, associated with blocked tumourigenesis of the H-Ras and β-catenin 
mutants.  Thus, I next tested if the p21 compensatory mechanism is lost, will β-catenin 
activation result in progression to frank UCC.  
I generated the following cohorts: UroIICRE+p21-/- and UroIICRE+β-cateninexon3/exon3p21-/- 
(n= 6 and 16 respectively).  I then aged mice until tumour development. The UroIICRE+β-
cateninexon3/exon3p21-/- mice rapidly developed urothelial tumours (mean 237, median 238 days) 
in comparison to the UroIICRE+ p21-/- that were aged to 18 months with no urothelial 
phenotype (Figure 4.7). 
Indeed consistent with previous studies these tumours demonstrated evidence of proliferation 
by Ki67 staining as well as high levels of nuclear β-catenin and pERK1/2 (Figure 4.8 A-D). 
This time the lesions did not demonstrate any significant level of nuclear p53 or p21 (Figure 
4.8 E-F). This suggests that p21 plays a role in blocking β-catenin induced UCC. 
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Figure 4.7: Kaplan Meier curves of tumour free survival of UroIICRE+p21-/- (U p21) and 
UroIICRE+β-cateninexon3/exon3p21-/ (UB p21) cohorts 
Log Rank test p<0.0001 
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Figure 4.8: Histology of UroIICRE+ β-cateninexon3/exon3p21-/- mouse.  
H&E reveals bladder tumour (A) with upregulation of Ki67, β-catenin and pERK1/2 (B-D). 
There is minimal upregulation of p53 and p21 (E&F). Black bar measures 200µm (20x 
magnification). 
(At least 3 samples from each cohort stained and representative images are shown above). 
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4.2.4. Human UCC demonstrate correlation between Wnt and Ras activation 
 
In human urothelial cancer, a number of studies have suggested Wnt signalling is important. 
Of particular note is the demonstration that nuclear β-catenin is associated with a poor 
prognosis, and methylation of the genes encoding inhibitors of Wnt signalling, the SRFPs, act 
as markers of a bad prognosis (Marsit et al., 2005, Urakami et al., 2006a, Urakami et al., 
2006b). Indeed the methylation of these genes has been suggested as a marker of invasive 
bladder carcinoma.   
I next looked at human bladder UCC using a tissue microarray of 80 cases, 60 UCC 
(transitional cell carcinomas [TCC]) and 20 benign controls (Folio biosciences, OH, USA). 
Using the histoscore technique I was able to demonstrate a significant correlation between 
upregulation of β-catenin and activation of pERK1/2 (n=24/56, cc=0.333, p=0.012, SPSS 
v15) (Figure 4.9 & Figure 4.10). This is further indication that activation of the Ras pathway 
is essential for Wnt driven UCC to progress.  
The presence of nuclear p21 was observed in a third of the tumour samples (20 out of 60), 
which did not show significant association with tumour grade, probably due to the small 
cohort size.  I next wanted to look at correlation between upregulation of β-catenin and loss of 
p21 (Figure 4.9). However I found no evidence for any correlation between the 2 groups 
(cc=0.174, p=0.199). Interestingly, there was an expected significant correlation between 
upregulation of pERK1/2 and p21 loss (cc=0.369, p=0.005).   
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Figure 4.9: Human Bladder UCC TMA 
IHC of human bladder transitional cell carcinoma revealing upregulation of β-catenin (A&D), 
and corresponding upregulation of pERK1/2 (B&E), with minimal expression of p21 (C&F) 
compared to wildtype.  
Each core size is 1.5mm. 
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Figure 4.10: Correlation between β-catenin and pERK1/2 in Human Bladder UCC TMA 
Scatterplot demonstrating correlation between β-catenin and pERK1/2. 
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4.3. Discussion 
I have shown that activation of the Ras pathway alone is not enough to drive UCC.  However, 
activation of Wnt signalling strongly cooperates with other genetic events that occur in 
bladder cancer such as activation of Ras to drive carcinoma formation.  Our tumours never 
became invasive, suggesting co-operation of both mutations along the non-invasive/papillary 
UCC pathway.  It must be noted that both our Ras mice are different in respect to knock-
in/overexpression status.  I utilised the Lox-Stop-Lox K-Ras conditional mouse strain, in 
which expression of oncogenic K-Ras G12D is controlled by a removable transcriptional 
termination Stop element (Jackson et al., 2001).  Since the endogenous K-Ras locus is 
targeted in the K-Ras G12D strain, only endogenous levels of oncogenic K-Ras G12D are 
expressed (not overexpression).  In contrast, the H-Ras model is an overexpression of the 
oncogenic rabbit transgene (point mutation at codon 61 of the second exon converting CAG 
(encoding glutamine) to CTG (leucine) (Zhang et al., 2001).  Transgene copy number varied 
from 2 copies (low copy, UCC from 10-26 months of age) to 48 copies (high copy, UCC from 
4 months of age).  This may account for the difference in phenotypes, namely no phenotype in 
the UroIICRE+K-RasG12D/+ and pronounced hyperplasia in the overexpression H-RasQ61L 
model.  However it is difficult to make any definitive conclusions since we are dealing with 
different Ras alleles.  In anticipation I am currently repeating these experiments with a Lox-
Stop-Lox H-Ras G12V conditional mouse strain, which will allow us to make direct 
comparisons.   
Interestingly, despite modelling all these mutations in the murine urothelium, these tumours 
remain non-invasive and do not metastasis despite extended follow-up.  Again this may be 
due to our tumours not being “aggressive” enough, and by inserting p53 mutations these 
tumours may become locally invasive and ultimately metastatic, as has been previously 
outlined in the colon by our group (Muller et al., 2009).  These experiments have been set up 
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and I am currently ageing these mice to demonstrate whether these mice develop muscle 
invasive UCC.  
Given the experimental data from this chapter, it appears p21 acts as a bladder specific block 
to proliferation (and tumourigenesis) in the UroIICRE+ β-cateninexon3/exon3 and H-RasQ61L 
mice.  This indeed confirmed to be the case since when p21 was knocked out in these bladder 
lesions they rapidly progressed to UCC. The human UCC correlations of loss of p21 must be 
viewed with a critical eye since, as I have demonstrated that p21 is upregulated early, as a 
bladder specific compensatory mechanism to block proliferation and tumourigenesis.  Our 
TMA’s cohort of tumours is of varying grades and does not differentiate between non-
invasive and muscle invasive disease.  It will be important to interrogate a larger cohort with 
both early and late disease.  My working hypothesis is that p21 upregulation would be 
observed early in precursor lesion (CIS) and low grade tumours, whilst the more aggressive 
and muscle invasive tumours will show loss of their compensatory mechanism and p21 will 
not be expressed at the protein level. 
It will be interesting to treat these mice with an ERK inhibitor in order to investigate whether 
pERK formation is required for UCC formation in the double mutants.  It will also be 
particularly interesting to look at the UroIICRE+ β-cateninexon3/exon3 H-RasQ61L lesions to see 
whether the fall in pERK1/2 is accompanied by a fall in p21 
Taken together, I demonstrated the causative role of β-catenin in the formation of UCC in 
vivo and provide evidence that activating mutations in the Wnt pathway promote UCC when 
combined with other oncogenic mutations (Ras) and loss of tumour suppressors (p21).  
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Chapter 5: The FGFR3 mutation cooperates with K-Ras and β-Catenin 
mutations to promote skin and lung but not bladder tumour formation 
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5.1. Introduction 
 
In the last chapter I investigated whether Ras mutations were sufficient to drive the murine 
urothelium to develop non-invasive papillary UCC, as is seen with the human disease.  I was 
able to demonstrate that in the case of K-Ras G12D point mutation no tumour forms unless 
this is combined with Wnt pathway upregulation.  In the case of the overexpressing H-Ras 
oncogene, I found that Wnt pathway activation greatly reduced the tumour latency.  I have 
also previously demonstrated that mice with β-catenin overexpression co-operates with 
PTEN/p21 loss to drive tumourigenesis along the non-invasive papillary pathway.   
Thus the aim of this final chapter was to investigate the role of oncogenic FGFR3 mutation on 
the murine urothelium in vivo.  Given our previous experiments, I also wished to test this on 
the background of Wnt pathway upregulation. 
Somatic mutations in Fibroblast Growth Factor Receptor 3 (FGFR3) have been identified at a 
high frequency in the superficial UCC (70%) (Knowles, 2007). FGFR3 is a receptor tyrosine 
kinase that is known to mediate the effects of fibroblast growth factors (FGFs). Several 
studies have shown that mutations of FGFR3 in the bladder is strongly associated with a low 
tumor grade and stage (Billerey et al., 2001, Lamy et al., 2006, Jebar et al., 2005, Lindgren et 
al., 2006). When these activating mutations occur in the germ-line, they are known to cause 
several autosomal dominant human skeletal dysplasia syndromes (Muenke and Schell, 1995).  
Although human studies strongly suggest the importance of FGFR3 mutations in cancer, thus 
far they have been uninformative on the precise mechanistic role of FGFR3 mutations in 
tumour formation and progression. Generation of relevant mouse model is essential not only 
for the investigation of mechanism but also for testing potential therapeutic approaches. In 
this study, I assessed the role of two potent, activating mutations of FGFR3 found in UCC in 
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the initiation and development of bladder cancer in vivo as a sole driver, and in synergy with 
β-catenin and K-Ras mutations. 
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5.2. Results 
5.2.1. Targeting of the Fgfr3 mutations in the bladder 
 
I bred UroIICRE+ mice to lines carrying Fgfr3 K644E and Fgfr3 K644M mutations (murine 
equivalent of human K652E and K652M, respectively) (Iwata et al., 2000, Iwata et al., 2001). 
Both lines carry a neomycin resistant gene (neo) flanked by loxP sites in the intron 5’-
upstream of the exon harboring the K644 mutations. This exogenous gene insertion was 
designed to suppress the expression of Fgfr3 mutant allele in the absence of Cre 
recombination. In the presence of Cre, the neo gene is excised allowing expression of the 
mutant Fgfr3 protein. In the offspring of UroIICRE+Fgfr3+/K644E and UroIICRE+Fgfr3+/K644M, 
pattern and approximate levels of the Fgfr3 protein expression were similar to those of the age 
matched wildtype (Figure 5.1 A,B,E & Figure 5.2). In wildtype mice, Fgfr3 expression 
revealed occasional scattered cells in the urothelium at P2 (Postnatal day 2) and 5 months; 
whilst at 12 months its expression was uniformly detected in the urothelium (Figure 5.1 D-F).  
I did not notice any difference in staining expression at earlier 3-month timepoint in the 
UroIICRE+Fgfr3+/K644E and UroIICRE+Fgfr3+/K644M mice compared to the 12-month 
timepoint. 
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Figure 5.1 Cre recombination and expression of Fgfr3 in the urothelium 
Immunohistochemistry (IHC) for Fgfr3 (arrowhead) in the urothelium of 
UroIICRE+Fgfr3+/K644E (A), UroIICRE+Fgfr3+/K644M (B), as well as P2 (postnatal day 2) (C), 5 
month (D) and 12 month-old (E) wildtype urothelium. This revealed that expression levels 
and location of Fgfr3 were comparable in the mutant and wildtype at 12 month. Scale bar 
represents 200 µm in B-F. 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 5.2 FGFR3 positive cells in 12 month old Wildtype, UroIICRE+Fgfr3+/K644E and 
UroIICRE+Fgfr3+/K644M   
20x magnification, 3 fields per murine bladder, 3 mice for each cohort sampled. 
Thick line represents median, box represents inter-quartile range and whiskers represent 
range. 
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5.2.2. Fgfr3 mutation alone does not drive tumourigenesis of the bladder 
 
To investigate the role of Fgfr3 mutations as a driver of UCC, I aged the 
UroIICRE+Fgfr3+/K644E and UroIICRE+Fgfr3+/K644M mutant mice to 18 months (n=20 each 
genotype). No mouse developed urothelial hyperplasia, dysplasia or carcinoma when aged to 
18 months of age (Figure 5.3 & 5.4 A,E,I). 
Upon 2 hours of in vivo incorporation of BrdU in our 12 month old cohort, no apparent 
positivity was observed by IHC with anti-BrdU antibody, indicating that little or no cell 
proliferation took place in the urothelium either in the wildtype or in the mutant cohorts 
(Figure 5.4 B,F,J). I next examined the known core signalling pathways downstream of 
FGFR. A strong upregulation of pERK1/2 was observed in both UroIICRE+Fgfr3+/K644E and 
UroIICRE+Fgfr3+/K644M mutants compared to wildtype (Figure 5.4 C,J,K & Figure 5.5). This 
was accompanied by an upregulation of Sprouty2 levels (Figure 5.4 H,L & Figure 5.5). No 
significant pAKT (Ser473) or p-mTOR staining was present in the Fgfr3 mutant cohorts 
similar to wildtype (Figure 5.6). 
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Figure 5.3 Bladder H&Es from 12 month old Wildtype, UroIICRE+Fgfr3+/K644E and 
UroIICRE+Fgfr3+/K644M mice 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 5.4 Fgfr3 mutation is not the sole driver of tumourigenesis in the bladder.  
The samples are from 12-month old Wildtype (A-D), UroIICRE+Fgfr3+/K644E (E-H) and, 
UroIICRE+Fgfr3+/K644M (I-L). Haematoxylin and eosin (H&E) staining showed no apparent 
lesions in the urothelium in all Fgfr3 mutants (A,E,I). No significant cell proliferation was 
observed (as assessed by 2 hours of in vivo BrdU incorporation) (B,F,J). Upregulation of 
pERK1/2 (J,K) and Sprouty2 (H,L) were observed in Fgfr3 mutant mice, comparing to 
Wildtype (C,D). Scale bar represents 200 µm in all panels.  
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 5.5 Further images showing upregulation of pERK1/2 and Sprouty2: 
In 12-month-old UroIICRE+Fgfr3+/K644E (D-F, M-O), UroIICRE+Fgfr3+/K644M (G-I, P-
R) compared to wildtype bladders (A-C, J-L). Scale bar represents 200 µm in all panels.  
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 5.6 Role of the AKT-mTOR pathway in mutant models 
The samples are from 12-month old Wildtype (A-B), UroIICRE+Fgfr3+/K644E (C-D), 
UroIICRE+Fgfr3+/K644M (E-F), UroIICRE+Fgfr3+/K644EK-RasG12D/+ (G-H), and 
UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ (I-J). Minimal upregulation of pAKT and p-mTOR 
was observed in all mutant cohorts compared to wildtype. Red arrowhead in (I) indicates the 
area of hyperproliferation. Scale bar represents 200 µm in all panels.  
(At least 3 samples from each cohort stained and representative images are shown above). 
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Given our previous experimental work I next examined the role of β-catenin activating 
mutations in the context of FGFR3 mutation, UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ (n=27) 
(Harada et al., 1999).  In order to drive deregulated Wnt signalling, I again used mice that 
carry a dominant allele of the β-catenin gene in which exon3 is flanked by loxP sequences 
(Harada et al., 1999). Although areas of hyperproliferation were observed in the bladders of 
UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ from approximately 3 months of age in 100% of mice 
(n=20), equivalent lesions were found in the UroIICRE+β-cateninexon3/+ urothelium. In both 
groups these lesions never progressed further upon examination up to 12 months (Figure 5.7 
E); however they did show incorporation of BrdU (Figure 5.7F). Similar to above described 
single and double mutants, upregulation of pERK1/2 and Sprouty2 was also observed (Figure 
5.7 G,H). The areas of hyperproliferation that were observed in UroIICRE+β-cateninexon3/+ 
mice had comparable levels of upregulation of BrdU, pERK1/2 and Sprouty2 in the lesions 
(data not shown), indicating that Fgfr3 mutations are not contributing to urothelial hyperplasia 
in UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ mice. I did not observe any upregulation of 
pAKT(Ser473) or p-mTOR (Figure 5.6). Taken together, these data suggest that FGFR3 
mutation does not cooperate with activation of Wnt signaling to drive UCC.   
 
I next examined the role of oncogenic K-Ras G12D (Jackson et al., 2001) in 
UroIICRE+Fgfr3+/K644EK-RasG12D/+ (n=23).  Upon aging to 12 months, no 
UroIICRE+Fgfr3+/K644EK-RasG12D/+ mice developed urothelial hyperplasia, dysplasia or 
carcinoma (Figure 5.7 A) and no apparent changes in BrdU incorporation were observed 
(Figure 5.7 B). Similar to the single mutants, a strong upregulation of pERK1/2 (Figure 5.7 C) 
as well as an accompanying upregulation of Sprouty2 was observed (Figure 5.7 D). Similar 
levels of upregulation of pERK1/2 and Sprouty2 were observed in the UroIICRE+K-RasG12D/+ 
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urothelium (data not shown). I observed minimal levels of upregulation of pAKT(Ser473) and 
p-mTOR in the UroIICRE+Fgfr3+/K644EK-RasG12D/+ cohorts (Figure 5.6). 
 
 
 
 
 
Figure 5.7 Fgfr3 mutation in combination does not lead to tumourigenesis in the bladder 
The samples are from 12-month old UroIICRE+Fgfr3+/K644EK-RasG12D/+ (A-D), and 
UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ (E-H). Haematoxylin and eosin (H&E) staining 
showed no apparent lesions in the urothelium in UroIICRE+Fgfr3+/K644EK-RasG12D/+ mice (A) 
except for the compound model with β-cateninexon3/+ (E) where hyperplasia was observed (red 
arrowhead, also in G,H). No significant cell proliferation was observed (as assessed by 2 
hours of in vivo BrdU incorporation) (B) except for the area of hyperplastic lesion in 
UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ (arrowhead) (F). Upregulation of pERK1/2 (C,G) and 
Sprouty2 (D,H) were observed in Fgfr3 mutant mice, comparing to Wildtype. Scale bar 
represents 200 µm in all panels.  
(At least 3 samples from each cohort stained and representative images are shown above). 
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5.2.3. Formation of lung tumors in the UroIICre+Fgfr3+/K644Eβ-cateninexon3/+ mice 
 
In contrast to observations in the urothelium, 28% (8/28) of the UroIICRE+Fgfr3+/K644Eβ-
cateninexon3/+ mice by 1 year of age developed lung tumours (Figure 5.8). Imaging with the 
OV100 microscope showed a strong GFP signal in the lung tumor, indicating that the 
UroIICRE-driven recombination occurred in these tumors (Figure 5.9 A). I did not see any 
signal in the normal lung tissue. These tumors resembled most closely solitary fibrous tumour 
(SFT) of the lung (Figure 5.9 B). Up to a third of SFTs exhibit nuclear β-catenin consistent 
with our murine models (Andino et al., 2006).  Solitary fibrous tumours (SFTs) were termed 
hemangiopericytomas (HPCs) in the past. According to the World Health Organization 
(WHO), these tumours are mesenchymal neoplasms of subendothelial origin that can be 
found mostly in the pleura but also in extraserosal sites, such as lung, mediastinum, liver, 
head and neck, and deep soft tissues of the extremities. Most SFTs behave as slowly growing, 
painless masses (Kouki et al., 2008). In our murine tumours strong BrdU positivity indicated 
rapid cell proliferation (Figure 5.9 C). In addition tumors showed high levels of nuclear β-
catenin by IHC, consistent with the activation of β-catenin due to Cre mediated excision of 
exon 3 (Figure 5.9 D). No lung tumors were observed in the UroIICRE+β-cateninexon3/+ mice 
aged up to 18 months (n=20); therefore the FGFR3 mutation is cooperating with β-catenin 
activation to drive lung tumourigenesis. 
Increased levels of pAKT (Ser473) and p-mTOR were observed (Figure 5.9 E,F), suggesting 
the involvement of AKT pathway in tumourigenesis. However, I found minimal upregulation 
of pERK in these tumors with accompanying upregulation of Sprouty2 (Figure 5.9 G,H). 
I compared these tumors to phenotypically similar lung tumours found in UroIICRE+β-
cateninexon3/+K-RasG12D/+ mice. In these tumors, I found that rather than having high levels by 
the pAKT pathway, they was dramatic upregulation of pERK1/2, with corresponding fall in 
Sprouty2 expression (Figure 5.9 I-L). When I measured staining intensity using a weighted 
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Histoscore technique, I found statistically significant increases in both nuclear and 
cytoplasmic pERK1/2 staining in the UroIICRE+β-cateninexon3/+K-RasG12D/+ cohort compared 
to the UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ mice (p<0.001, Figure 5.10 A,B) (Kirkegaard et 
al., 2006). Conversely, I found much higher levels of pAKT(Ser473) staining in lung tumors 
of the UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ mice in comparison to UroIICRE+β-
cateninexon3/+K-RasG12D/+ mice (p<0.001, Figure 5.10 C,D).  Consistent with this, p-mTOR 
staining was also upregulated in UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ mice.  As observed 
with the IHC, when quantified I observed increased levels of membranous and cytoplasmic 
Sprouty2 staining in the UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ mice in comparison to 
UroIICRE+β-cateninexon3/+K-RasG12D/+ (p<0.05) (Figure 5.10 E&F). 
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Figure 5.8 Kaplan-Meier curve of UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ (Fgfr3 β-Cat) 
mice 
UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ (Fgfr3 β-Cat) cohorts showed accelerated lethality due 
to tumour formation comparing to, UroIICRE+β-catenin exon3/+(B-cat), and 
UroIICRE+Fgfr3+/K644E (Fgfr3). Long rank test reveals significant reduction in survival in 
Fgfr3 B-cat colony compare to Fgfr3/B-cat colonies (p<0001). 
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Figure 5.9 Formation of lung tumor in the UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ model. 
Ex-vivo GFP imaging by OV100 (Olympus) demonstrated Cre-mediated recombination in the 
lung tumors of UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ (A). H&E staining shows the lung 
tumour (B), in which BrdU staining indicates high cell proliferation in the lesion (C).  Strong 
nuclear staining indicates the activation of β-Catenin in the tumour (D). pAKT(Ser473) (E), 
p-mTOR(Ser2448) (F) and Sprouty2 (H) were all upregulated in the lung tumor in 
UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+, with minimal pERK (G) staining. In comparison, lung 
tumors in UroIICRE+β-cateninexon3/+K-RasG12D/+ show minimal upregulation of pAKT (I) and 
p-mTOR (J), but strong upregulation of pERK (K) with very little Sprouty2 increase (L). 
Scale bar represents 200 µm. 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 5.10 Box plots quantifying immunostaining of pERK1/2, pAKT(Ser473) and 
Sprouty2 in lung tumors of UroIICRE+β-cateninexon3/+K-RasG12D/+ and 
UroIICRE+Fgfr3+/K644Eβ-cateninexon3/+ mice   
For each tissue section (n=5), the percentage of immunoreactivities in the nucleus and 
cytoplasm was evaluated at × 40 magnification. Staining intensity was categorized into the 
percentage of cells with 0, 1, 2 and 3, denoting negative, weak, moderate and strong staining, 
respectively. The final histoscore was calculated from the sum of (1 × % weakly positive 
tumour cells) + (2 × % moderately positive tumour cells) + (3 × % strongly positive tumour 
cells) positive tumour cells with a maximum histoscore of 300.  Statistics were performed 
using the Mann Whitney test. 
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5.2.4. Skin Papilloma formation in UroIICre+Fgfr3+/K644EK-RasG12D/+ mice 
 
By 1 year of age, 10/21 (48%) of UroIICre+Fgfr3+/K644EK-RasG12D/+ cohort developed 
papilloma (Figure 5.11, Figure 5.12 A,C). These tumours reached 1 cm of size by a median of 
220 days (mean 249 days). To ensure the tumour formation was due to sporadic Cre 
recombination, I crossed the UroIICRE+Fgfr3+/K644EK-RasG12D/+ mice to Z/EGFP reporter. I 
observed a strong GFP signal within these papillomas, indicating the Cre recombination 
(Figure 5.12 E), with no expression in normal skin. In contrast, no papilloma formation was 
observed in the UroIICRE+K-RasG12D/+ cohort aged up to 18 months (n=20), indicating that 
Fgfr3 mutation cooperates with K-Ras mutation to drive papilloma formation. The papillomas 
in the UroIICRE+Fgfr3+/K644EK-RasG12D/+ cohort incorporated BrdU (Figure 5.13 A), 
indicating the increase in cell proliferation. Mechanistically, tumour formation was associated 
with a robust activation of pERK1/2 (Figure 5.13 C). Distinct from the observation in the 
urothelium of these mice, an increased level of Sprouty2 was not observed (Figure 5.13 E), 
which either suggests that the negative feedback counteracting oncogenic MAPK pathway has 
not occurred in this line or that all the Sprouty2 has been lost (e.g. hypermethylation in the 
tumours). Levels of pAKT (Ser473) and p-mTOR were unchanged (Figure 5.13 G,I).  I 
noticed upregulation of p21 and pMEK (Figure 5.13 K,M)  
I compared this phenotype to UroIICRE+K-RasG12D/+Ptenfl/+ mice that regularly develop 
papillomas (8/19 or 42%) (Figure 5.12 B,D). I found a similar increase in BrdU incorporation, 
but this time with much lower levels of nuclear pERK1/2 observed in the lesion (Figure 5.13 
B,D). Sprouty2 was upregulated (Figure 5.13 F) similar to urothelium phenotype of Fgfr3 
mutant models, while elevated levels of pAKT (Ser473) and p-mTOR were also observed 
(Figure 5.13 H,J).  Similarly I observed upregulation of p21 and pMEK (Figure 5.13 L,N).  I 
also measured staining intensity using a modified Histoscore in the papillomas from each 
cohort (n=5). I found statistically significant increases in both nuclear and cytoplasmic 
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pERK1/2 staining in the UroIICRE+Fgfr3+/K644EK-RasG12D/+ compared to the UroIICRE+K-
RasG12D/+Ptenfl/+ mice (p<0.001/0.05 respectively, Figure 5.14 A,B). Conversely, I found 
much higher levels of pAKT(Ser473) staining in papillomas of the UroIICRE+K-
RasG12D/+Ptenfl/+  mice in comparison to UroIICRE+Fgfr3+/K644EK-RasG12D/+ mice (p<0.001, 
Figure 5.14 C,D). These results indicate that although Sprouty-mediated suppression of 
MAPK signaling is intact, activation of AKT pathway may contribute to tumourigenesis in 
this model.  
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Figure 5.11 Kaplan-Meier curve of UroIICRE+Fgfr3+/K644EK-RasG12D/+ (Fgfr3 K–Ras) 
mice 
UroIICRE+Fgfr3+/K644EK-RasG12D/+ (Fgfr3 K–Ras) cohorts showed accelerated lethality due to 
tumor formation comparing to, UroIICRE+K-RasG12D/+ (K-Ras), and UroIICRE+Fgfr3+/K644E 
(Fgfr3). The shorter survival of UroIICRE+Fgfr3+/K644EK-RasG12D/+ mice compared to control 
cohorts reflects the fact that I have sacrificed the animals when the tumor size reached 1 cm.  
Log rank p<0.001 for Fgfr3 K-Ras vs. Fgfr3/K-Ras cohorts. 
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Figure 5.12 Formation of papilloma lesions in the UroIICRE+Fgfr3+/K644EK-RasG12D/+ 
model 
H&E staining of papilloma samples are from 12 month-old of UroIICRE+Fgfr3+/K644EK-
RasG12D/+ (A,C) and UroIICRE+K-RasG12D/+Ptenfl/+ mice (B,D). OV100 whole-mouse GFP 
imaging indicated Cre-recombined cells in papilloma (E). 
Red scale bar represents 400 µm and black scale bar represents 200 µm. 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 5.13 Formation of papilloma lesions in the UroIICRE+Fgfr3+/K644EK-RasG12D/+ 
model 
Papilloma samples are from 12 month-old of UroIICRE+Fgfr3+/K644EK-RasG12D/+ 
(A,C,E,G,I,G,M) and UroIICRE+K-RasG12D/+Ptenfl/+ mice (B,D,F,H,J,L,N). BrdU 
immunoreactivity demonstrated cell proliferation (A,B). Upregulation of pERK1/2 was 
observed in UroIICRE+Fgfr3+/K644EK-RasG12D/+ (C) as observed in the urothelium, and in the 
control UroIICRE+K-RasG12D/+Ptenfl/+ mice (D). However, upregulation of Sprouty2 was not 
present (E). Neither pAKT(Ser473) nor p-mTOR was upregulated in papillomas formed in 
UroIICRE+Fgfr3+/K644EK-RasG12D/+ mice (G,I). In contrast, in UroIICRE+K-RasG12D/+Ptenfl/+ 
papillomas, Sprouty 2 (F), pAKT(Ser473) (H) and p-mTOR (J) was upregulated. I noticed 
significant upregulation of p21 in the papillomas (K,L), as well as pMEK (M,N) 
Scale bar represents 200 µm in all panels. 
(At least 3 samples from each cohort stained and representative images are shown above). 
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Figure 5.14 Box plots quantifying immunostaining of pERK1/2 and pAKT(Ser473) in 
papillomas of UroIICRE+Fgfr3+/K644EK-RasG12D/+ and UroIICRE+K-RasG12D/+Ptenfl/+ mice  
For each tissue section (n=5), the percentage of immunoreactivities in the nucleus and 
cytoplasm was evaluated at × 40 magnification. Staining intensity was categorized into the 
percentage of cells with 0, 1, 2 and 3, denoting negative, weak, moderate and strong staining, 
respectively. The final histoscore was calculated from the sum of (1 × % weakly positive 
tumour cells) + (2 × % moderately positive tumour cells) + (3 × % strong of experience) 
positive tumour cells with a maximum histoscore of 300.  Statistics were performed using the 
Mann Whitney test. 
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5.3. Discussion 
 
In summary, I have demonstrate here that activating mutations of FGFR3 are unlikely to be 
the sole initiating factor for UCC (Figure 2) and that FGFR3 does not cooperate with either 
Wnt or Ras signaling to drive UCC. Given that FGFR3 mutations are thought to be mutually 
exclusive with HRAS mutations and only rarely mutated with p53 this suggests that 
generating mouse models that recapitulate superficial UCC that have FGFR3 mutations will 
be difficult and will require greater knowledge of the genetic changes that accompany FGFR3 
mutations (Puzio-Kuter et al., 2009, Wu, 2005).   
The study showed that somatic FGFR3 mutations caused upregulation of the MAPK pathway 
in the urothelium, which accompanied upregulation of Sprouty2, one of the feedback 
inhibitors of the MAPK pathway. I speculate that this may be one of the mechanisms by 
which UCC is normally prevented. In case of lung tumours in UroIICRE+Fgfr3+/K644Eβ-
cateninexon3/+ cohort, a strong upregulation of the PI3K-pAkt and Wnt-β-Catenin pathways 
may underlie tumourigenesis. In contrast, in papillomas in UroIICRE+Fgfr3+/K644EK-
RasG12D/+, no concomitant upregulation of Sprouty2 had occurred, potentially leading to 
uncontrolled activation of MAPK pathway in the absence of a negative feedback mechanism. 
It is tempting to propose that these differential downstream signaling profiles are the basis of 
tumourigenesis in the presence of Fgfr3 mutations in a tissue-specific fashion (Figure 5.15). It 
would be interesting to assess if downregulation of Sprouty2 in our system resulted in 
formation of UCC.  Using OncomineTM 
(http://www.oncomine.org/geneModule/differential/filterStore.jsp) Lindgren and colleagues 
have demonstrated that in FGFR3 mutant bladder cancer there is a downregulation of Sprouty 
2 at the mRNA level (p=0.015) (Lindgren et al., 2006). In the same study they find that 
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Sprouty2 mRNA levels are downregulated as the disease progresses from Grade 1 to 3 
(p=0.015).  
 
 
 
 
 
 
Figure 5.15 Current model of signaling pathways that could contribute to tumour 
formation in the presence of Fgfr3 mutations in specific organ systems 
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FGFR3 is a membrane tyrosine kinase that is known to mediate the effects of fibroblast 
growth factors (FGFs). Somatic mutations in FGFR3 have been identified at a high frequency 
in bladder cancer (35-41%) (Cappellen et al., 1999, Sibley et al., 2001a, Sibley et al., 2001b). 
In bladder, the frequency of FGFR3 mutation was higher in superficial tumours than invasive 
ones (Billerey et al., 2001, van Rhijn et al., 2001, Kimura et al., 2001). The mutations found 
in bladder cancer are specific and not found in other primary tumours and tumour cell lines 
(Sibley et al., 2001a, Sibley et al., 2001b, Karoui et al., 2001). However, frequent mutation 
has been detected in seborrhoeic keratoses and epidermal naevi (Hafner et al., 2007a, Hafner 
et al., 2007b, Hafner et al., 2006).   
K652E and K652M (equivalent of murine K644E and K644M respectively) mutations, which 
I described in this thesis, are found in human UCC but are much less frequent (3%) than the 
S249C which account for 67% of the FGFR3 mutations in bladder cancer (Knowles 2008). 
Thus it is possible that S249C mutations are more oncogenic in the bladder. In vitro, both 
S249C and K652E/K652M mutations are shown to constitutively increase the FGFR3 kinase 
activity, albeit with different mechanisms. S249C is known to cause ligand-independent 
dimerization, while K652E/K652M promotes conformational change that favors the higher 
auto-phosphorylation and its kinase activity can be further enhanced by additional ligand 
stimulation (Naski et al., 1996, d'Avis et al., 1998). Upon measuring transcription-inducing 
activity by fos-luciferase reporter assay, K644E mutant protein was actually twice as active as 
S249C mutant in the absence of ligand (d'Avis et al., 1998).  However preliminary data 
suggests that, transgenic mice with human FGFR3IIIb isoform with S249C mutation did not 
show any tumors in the bladder up to 1 year of age (M. Knowles personal communication). 
This strongly indicates that UCC formation requires an additional mutation(s) to that in 
FGFR3.   
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The skin papilloma and lung tumours observed in our study with Fgfr3 mutations are relevant 
in human cancer, as FGFR3 mutations are found in such tumours (Woenckhaus et al., 2006, 
Hafner et al., 2007a, Cortese et al., 2008). Studies by Logie et al showed that the transgenic 
mice, K5-(S249C)FGFR3, that expresses FGFR3 S249C mutation in the basal cells of the 
epidermis driven by bovine keratin 5 promoter, developed benign skin tumours (Logie et al., 
2005). In these mice, the skin tumours are observed from 3-4 months of age and lesions 
enlarged as the animals aged, without showing regression. To further this work we are 
investigating activation of FGFR3 in the skin using the skin specific K14-Cre ER with and 
without Ras activation (Indra et al., 2000).  We currently have a number of FGFR3 inhibiting 
antibodies in the lab that I would wish to try in these mice to assess tumour response. 
Recent work has elegantly demonstrated knockdown of FGFR3 expression suppressed growth 
of bladder cell lines and mouse xenograft models (Qing et al., 2009). Furthermore, FGFR3-
specific monoclonal antibody (R3Mab) significantly inhibited growth and progression of 
xenograft tumors that harboured the S249C and K650E mutations (Qing et al., 2009).  Further 
studies of the FGFR3 signaling pathway deregulated in UCC is therefore essential, firstly to 
allow one to stratify patients according to risk of progression/recurrence, and secondly to aid 
in patient selection for either single agent or combination therapy with small molecule and 
monoclonal antibody-based treatments in the future (Knowles, 2008, Black et al., 2007, Qing 
et al., 2009).  Moreover identifying the cooperating molecular events that occur alongside 
FGFR3 mutation to drive UCC will aid development of genetic models of UCC to test 
combinatorial therapies. 
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Chapter 6: Summary and Concluding Remarks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
196 
 
6.1. Summary 
 
Manipulation of the mouse genome has allowed researchers to analyse the effect of specific 
genetic alterations on the development of urothelial cell cancer (UCC) in vivo.  We are able to 
analyse the molecular basis of initiation, invasion and progression to metastatic disease. 
Transgenic mice had improved the molecular characterisation of the divergent pathways of 
UCC and metastasis and help examine the crosstalk among different genetic mutations.  In the 
future one would hope that they identify new prognostic targets and novel therapeutic agents, 
as well as providing in vivo models to test these treatment regimes.  
In this thesis I hope I have achieved my initial aims and have shown that deregulated Wnt 
signalling plays a critical role in driving UCC both in the mouse (and the human).  I have 
demonstrated that Wnt signaling within the bladder urothelium is a progressor mutation of 
UCC in the background of mutations to other key oncogenic/tumour suppressor genes (PTEN, 
Ras p21, FGFR3).  Finally I have developed better murine models of human UCC that will 
allow pre-clinical trialling of new drug agents and assessment of treatment response. 
I showed that deregulated Wnt signalling on a background of PTEN loss leads to UCC that 
appears to be mTOR dependent (regression with rapamycin treatment). Similarly in our 
human UCC cohort we find that those patients that have high levels of Wnt signalling appear 
to correlate with those that have high levels of pAKT (and loss of PTEN). 
I next looked at oncogenic Ras signalling on the background of deregulated Wnt signalling 
and discovered similar results with both H-Ras and K-Ras causing UCC in the β-catenin 
mutant mouse. In our human cohort I demonstrated a correlation between upregulation of β-
catenin and pERK1/2.  However whether the pERK1/2 upregulation is solely due to Ras 
mutation is unlikely, making it interesting to sequence these tumours that upregulate β-catenin 
to assess Ras mutational status. 
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I observed that in our β-catenin urothelial lesions, as well as the H-Ras induced hyperplasia an 
upregulation of the p21 tumour suppressor. Thus, I next decided to knock-out p21 in this 
mouse and demonstrated again that p21 provides an essential block to the progression of 
deregulated Wnt induced tumourigenesis in the urine urothelium.  Although this upregulation 
was not confirmed by our human TMA, this is not unexpected due to the heterogenous grade 
and types of samples I had access to.  As a result I am expanding our cohort to look at early 
neoplastic (CIS) and low-grade tumours, where one would expect upregulation of p21. 
Similarly I attempted to test the functional significance of FGFR3 mutations as a “driver” of 
UCC. Thus I targeted the expression of mutated Fgfr3 to the murine urothelium using 
uroplakin II promoter. These FGFR3 mutations had no effect on bladder homeostasis or 
tumourigenesis up to 18 months of ages. Even when these mutations were combined with β-
Catenin or Ras activating mutations, no urothelial dysplasia or UCC was observed. This 
suggests that other alterations are required that can cooperate with FGFR3 activation to cause 
UCC. To further investigate the role of these co-operating mutations with FGFR3, I am 
currently breeding these mice with a transposon based method that utilises the synthetic 
Tc1/mariner family transposon Sleeping Beauty (SB) to induce tumourigenesis in vivo (Collier 
et al., 2005, Dupuy et al., 2005).  This synthetic SB transposon, called T2/Onc, can both trap 
upstream genes and promote downstream sequences.  This allows both inactivation of tumour 
suppressor genes and activation of oncogenes.  Since it is foreign DNA, the SB insertion sites 
can be readily cloned and rapidly characterised to implicate genes that are co-operating with 
FGFR3 to drive UCC in vivo. 
Interestingly, however, due to sporadic ectopic Cre recombinase expression in the lung and 
skin of these mice, FGFR3 mutation caused skin papilloma and promoted lung 
tumourigenesis in cooperation with K-Ras and β-Catenin activation, respectively.  
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All these results demonstrate that deregulated Wnt signalling plays a critical role in driving 
bladder cancer formation, in combination with activation of proto-oncogenes such as Ras (but 
not Fgfr3) and loss of tumour suppressor genes such as PTEN and p21. I also demonstrated 
that activation of FGFR3 can cooperate with other mutations to drive tumourigenesis in a 
context dependent manner and support the hypothesis that activation of FGFR signaling 
contributes to human cancer. Interestingly there was no single mutation that drove UCC, in 
contrast to the intestine, where mutation to Apc is seen as the key driving tumourigenesis 
(Polakis, 2000a).  It appears that bladder cancer is a more progressive disease, requiring 
combinations of mutation to drive the neoplastic phenotype. 
Although these models recapitulate various aspects of UCC, no one model has yet 
recapitulated all stages from pre-invasive disease to metastasis.  So we ask ourselves the 
question how we can improve these models and make them more relevant.  One avenue I am 
currently actively pursuing is modeling loss of wildtype p53/mutation of p53 in combination 
with out Wnt based cancer models to observe whether this will drive metastatic disease as in 
other tumours.  We are also considering using intravesical carcinogen treatments to 
investigate whether this will cooperate with the transgenic mutation found in our mice to 
drive muscle invasive UCC. 
Recent sequencing of human UCC by the Sanger Institute in Cambridge is reassuring and 
demonstrates that these mutations we are modelling in the mouse are indeed relevant in 
human UCC. 
(http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=byhist&ss=bladder&sn=urinaryra
ct&s=3).  Indeed it has demonstrated that APC mutations occur about 11% of tumour 
samples, confirming it is an important mutation in UCC.  Further work must be done, in 
particular on the aggressive muscle invasive tumours and their metastasis to properly 
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delineate which mutations are contributing to their malignant phenotype.  Then one can better 
model human conditions in the mouse.  Since bladder tumourigenesis in humans requires 
genetic events in a temporal sequence, the next generation of murine models will be inducible 
systems, allowing us to switch on and off genes in a bladder specific manner at different time 
periods, in different sequences and to different levels, enabling us better understand what is 
occurring in the human.  This in turn will allow us to better target treatment at a molecular 
level, initially in the murine model, and ultimately translatable into man. 
The models I describe will provide ideal platforms for trialling of Wnt pathway inhibitors, 
most likely in combination with MAPK/PI3K inhibitors, to assess tumour response.  This 
makes it important to be able to identify the Wnt dependents tumours.  This type of 
preclinical trialling is essential, since in the clinic cancer patients are moving towards more 
personalised medicine, where their treatments will be based on the unique molecular signature 
of their tumours. 
In summary murine models will continue to provide us with invaluable information about 
tumour biology, initiation and progression and ultimately identification of molecular markers, 
and further elucidation of molecular pathways.  These models will allow for preclinical 
studies regarding efficacy and tolerability of various anticancer agents in isolation and in 
combination, as well as assessment of ultimate response.  This will ultimately allows us to 
translate these findings to the clinical setting allowing us to prognosticate and ultimately 
render cancer patients disease free. 
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